Nucleic acids containing single nucleotide polymorphisms and methods of use thereof

ABSTRACT

The invention provides nucleic acids containing single-nucleotide polymorphisms identified for transcribed human sequences, as well as methods of using the nucleic acids.

RELATED APPLICATIONS

[0001] This application is a continuation-in-part of U.S. Ser. No. 09/442,849, filed Nov. 17, 1999, which claims priority to U.S. Ser. No. 09/442,129 and U.S. Ser. No. ______, both filed Nov. 16, 1999, all of which are entitled “Nucleic Acids Containing Single Nucleotide Polymorphisms and Methods of Use Thereof” and naming Richard Shimkets and Martin Leach as inventors, and to U.S. Ser. No. 60/109,024, filed Nov. 17, 1998. The contents of these applications are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[0002] The invention relates generally to nucleic acids and polypeptides and in particular to the identification of human single nucleotide polymorphisms based on at least one gene product that was not previously described.

BACKGROUND OF THE INVENTION

[0003] Sequence polymorphism-based analysis of nucleic acid is generally based on alterations in nucleic acid sequences between related individuals. This analysis has been widely used in a variety of genetic, diagnostic, and forensic applications. For example, polymorphism analyses are used in identity and paternity analysis, and in genetic mapping studies.

[0004] Several different types of polymorphisms in nucleic acid have been described. One such type of variation is a restriction fragment length polymorphism (RFLP). RFLPS can create or delete a recognition sequence for a restriction endonuclease in one nucleic acid relative to a second nucleic acid. The result of the variation is in an alteration the relative length of restriction enzyme generated DNA fragments in the two nucleic acids.

[0005] Other polymorphisms take the form of short tandem repeats (STR) sequences, which are also referred to as variable numbers of tandem repeat (VNTR) sequences. STR sequences typically that include tandem repeats of 2, 3, or 4 nucleotide sequences that are present in a nucleic acid from one individual but absent from a second, related individual at the corresponding genomic location.

[0006] Other polymorphisms take the form of single nucleotide variations, termed single nucleotide polymorphisms (SNPs), between individuals. A SNP can, in some instances, be referred to as a “cSNP” to denote that the nucleotide sequence containing the SNP originates as a cDNA.

[0007] SNPs can arise in several ways. A single nucleotide polymorphism may arise due to a substitution of one nucleotide for another at the polymorphic site. Substitutions can be transitions or transversions. A transition is the replacement of one purine nucleotide by another purine nucleotide, or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine, or the converse.

[0008] Single nucleotide polymorphisms can also arise from a deletion of a nucleotide or an insertion of a nucleotide relative to a reference allele. Thus, the polymorphic site is a site at which one allele bears a gap with respect to a single nucleotide in another allele. Some SNPs occur within, or near genes. One such class includes SNPs falling within regions of genes encoding for a polypeptide product. These SNPs may result in an alteration of the amino acid sequence of the polypeptide product and give rise to the expression of a defective or other variant protein. Such variant products can, in some cases result in a pathological condition, e.g., genetic disease. Examples of genes in which a polymorphism within a coding sequence gives rise to genetic disease include sickle cell anemia and cystic fibrosis. Other SNPs do not result in alteration of the polypeptide product. Of course, SNPs can also occur in noncoding regions of genes.

[0009] SNPs tend to occur with great frequency and are spaced uniformly throughout the genome. The frequency and uniformity of SNPs means that there is a greater probability that such a polymorphism will be found in close proximity to a genetic locus of interest.

SUMMARY OF THE INVENTION

[0010] The invention is based in part on the discovery of single nucleotide polymorphisms (SNPs) in regions of human DNA.

[0011] Accordingly, in one aspect, the invention provides nucleic acid sequences comprising nucleic acid segments of both publicly known and novel genes, including the polymorphic site. The segments can be DNA or RNA, and can be single- or double-stranded. Preferred segments include a biallelic polymorphic site.

[0012] The invention further provides allele-specific oligonucleotides that hybridize to a segment of a fragment shown in Table 1, column 4, or its complement. These oligonucleotides can be probes or primers. Also provided are isolated nucleic acids comprising a sequence shown in Table 1, column 4, in which the polymorphic site within the sequence is occupied by a base other than the reference bases shown in Table 1, columns 5 and 6.

[0013] The invention further provides a method of analyzing a nucleic acid from an individual. The method determines which base is present at any one of the polymorphic sites shown in Table 1. Optionally, a set of bases occupying a set of polymorphic sites shown in Table 1 is determined. This type of analysis can be performed on a number of individuals, who are tested for the presence of a disease phenotype.

[0014] In another aspect, the invention provides an isolated polynucleotide which includes one or more of the SNPs described herein. The polynucleotide can be, e.g., a nucleotide sequence which includes one or more of the polymorphic sequences shown in Table 1 and which includes a polymorphic sequence, or a fragment of the polymorphic sequence, as long as it includes the polymorphic site. The polynucleotide may alternatively contain a nucleotide sequence which includes a sequence complementary to one or more of these sequences, or a fragment of the complementary nucleotide sequence, provided that the fragment includes a polymorphic site in the polymorphic sequence.

[0015] The polynucleotide can be, e.g., DNA or RNA, and can be between about 10 and about 100 nucleotides, e.g, 10-90, 10-75, 10-51, 10-40, or 10-30, nucleotides in length.

[0016] In preferred embodiments, the polymorphic site in the polymorphic sequence includes a nucleotide other than the nucleotide listed in Table 1, column 5 for the polymorphic sequence, e.g., the polymorphic site includes the nucleotide listed in Table 1, column 6 for the polymorphic sequence.

[0017] In other embodiments, the complement of the polymorphic site includes a nucleotide other than the complement of the nucleotide listed in Table 1, column 5 for the complement of the polymorphic sequence, e.g., the complement of the nucleotide listed in Table 1, column 6 for the polymorphic sequence.

[0018] In some embodiments, the polymorphic sequence is associated with a polypeptide related to one of the protein families disclosed herein. For example, the nucleic acid may be associated with a polypeptide related to angiopoietin, 4-hydroxybutyrate dehydrogenase, or any of the other proteins identified in Table 1, column 10.

[0019] In another aspect, the invention provides an isolated allele-specific oligonucleotide that hybridizes to a first polynucleotide containing a polymorphic site. The first polynucleotide can be, e.g., a nucleotide sequence comprising one or more polymorphic sequences recited in Table 1, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for the polymorphic sequence. Alternatively, the first polynucleotide can be a nucleotide sequence that is a fragment of the polymorphic sequence, provided that the fragment includes a polymorphic site in the polymorphic sequence, or a complementary nucleotide sequence which includes a sequence complementary to one or more polymorphic sequences in Table 1, provided that the complementary nucleotide sequence includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5. The first polynucleotide may in addition include a nucleotide sequence that is a fragment of the complementary sequence, provided that the fragment includes a polymorphic site in the polymorphic sequence.

[0020] In some embodiments, the oligonucleotide does not hybridize under stringent conditions to a second polynucleotide. The second polynucleotide can be, e.g., (a) a nucleotide sequence comprising one or more polymorphic sequences in Table 1, wherein the polymorphic sequence includes the nucleotide listed in Table 1, column 5 for the polymorphic sequence; (b) a nucleotide sequence that is a fragment of any of the polymorphic sequences; (c) a complementary nucleotide sequence including a sequence complementary to one or more polymorphic sequences disclosed herein in Table 1; and (d) a nucleotide sequence that is a fragment of the complementary sequence, provided that the fragment includes a polymorphic site in the polymorphic sequence.

[0021] The oligonucleotide can be, e.g., between about 10 and about 100 bases in length. In some embodiments, the oligonucleotide is between about 10 and 75 bases, 10 and 51 bases, 10 and about 40 bases, or about 15 and 30 bases in length.

[0022] The invention also provides a method of detecting a polymorphic site in a nucleic acid. The method includes contacting the nucleic acid with an oligonucleotide that hybridizes to a polymorphic sequence selected shown in Table 1, or its complement, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for the polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5. The method also includes determining whether the nucleic acid and the oligonucleotide hybridize. Hybridization of the oligonucleotide to the nucleic acid sequence indicates the presence of the polymorphic site in the nucleic acid.

[0023] In preferred embodiments, the oligonucleotide does not hybridize to the polymorphic sequence when the polymorphic sequence includes the nucleotide recited in Table 1, column 5 for the polymorphic sequence, or when the complement of the polymorphic sequence includes the complement of the nucleotide recited in Table 1, column 5 for the polymorphic sequence.

[0024] The oligonucleotide can be, e.g., between about 10 and about 100 bases in length. In some embodiments, the oligonucleotide is between about 10 and 75 bases, 10 and 51 bases, 10 and about 40 bases, or about 15 and 30 bases in length.

[0025] In some embodiments, the polymorphic sequence identified by the oligonucleotide is associated with a nucleic acid encoding polypeptide related to one of the protein families disclosed herein, the polymorphic sequence is associated with a polypeptide related to one of the protein families disclosed herein. For example, the nucleic acid may be associated with a polypeptide related to angiopoietin, 4-hydroxybutyrate dehydrogenase, or any of the other proteins identified in Table 1, column 10.

[0026] In a further aspect, the invention provides a method of determining the relatedness of a first and second nucleic acid. The method includes providing a first nucleic acid and a second nucleic acid and contacting the first nucleic acid and the second nucleic acid with an oligonucleotide that hybridizes to a polymorphic sequence selected disclosed in Table 1, or its complement, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for the polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5. The method also includes determining whether the first nucleic acid and the second nucleic acid hybridize to the oligonucleotide, and comparing hybridization of the first and second nucleic acids to the oligonucleotide. Hybridization of first and second nucleic acids to the nucleic acid indicates the first and second subjects are related.

[0027] In preferred embodiments, the oligonucleotide does not hybridize to the polymorphic sequence when the polymorphic sequence includes the nucleotide recited in Table 1, column 5 for the polymorphic sequence, or when the complement of the polymorphic sequence includes the complement of the nucleotide recited in Table 1, column 5 column for the polymorphic sequence.

[0028] The oligonucleotide can be, e.g., between about 10 and about 100 bases in length. In some embodiments, the oligonucleotide is between about 10 and 75 bases, 10 and 51 bases, 10 and about 40 bases, or about 15 and 30 bases in length.

[0029] The method can be used in a variety of applications. For example, the first nucleic acid may be isolated from physical evidence gathered at a crime scene, and the second nucleic acid may be obtained is a person suspected of having committed the crime. Matching the two nucleic acids using the method can establishing whether the physical evidence originated from the person.

[0030] In another example, the first sample may be from a human male suspected of being the father of a child and the second sample may be from a child. Establishing a match using the described method can establishing whether the male is the father of the child.

[0031] In another aspect, the method includes determining if a sequence polymorphism is the present in a subject, such as a human. The method includes providing a nucleic acid from the subject and contacting the nucleic acid with an oligonucleotide that hybridizes to a polymorphic sequence disclosed in Table 1, or its complement, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for the polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5. Hybridization between the nucleic acid and the oligonucleotide is then determined. Hybridization of the oligonucleotide to the nucleic acid sequence indicates the presence of the polymorphism in said subject.

[0032] In another aspect, the invention provides an isolated polypeptide comprising a polymorphic site at one or more amino acid residues, and wherein the protein is encoded by a polynucleotide including one of the polymorphic sequences in Table 1, or their complement, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for the polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5.

[0033] The polypeptide can be, e.g., related to one of the protein families disclosed herein. For example, polypeptide can be related to angiopoietin, 4-hydroxybutyrate dehydrogenase, ATP-dependent RNA helicase, MHC Class I histocompatibility antigen, or phosphoglycerate kinase.

[0034] In some embodiments, the polypeptide is translated in the same open reading frame as is a wild type protein whose amino acid sequence is identical to the amino acid sequence of the polymorphic protein except at the site of the polymorphism.

[0035] In some embodiments, the polypeptide encoded by the polymorphic sequence, or its complement, includes the nucleotide listed in Table 1, column 6 for the polymorphic sequence, or the complement includes the complement of the nucleotide listed in Table 1, column 6.

[0036] The invention also provides an antibody that binds specifically to a polypeptide encoded by a polynucleotide comprising a nucleotide sequence encoded by a polynucleotide including one or more of the polymorphic sequences in Table 1, or its complement. The polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for the polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5.

[0037] In some embodiments, the antibody binds specifically to a polypeptide encoded by a polymorphic sequence which includes the nucleotide listed in Table 1, column 6 for the polymorphic sequence.

[0038] Preferably, the antibody does not bind specifically to a polypeptide encoded by a polymorphic sequence which includes the nucleotide listed in Table 1, column 5 for the polymorphic sequence.

[0039] The invention further provides a method of detecting the presence of a polypeptide having one or more amino acid residue polymorphisms in a subject. The method includes providing a protein sample from the subject and contacting the sample with the above-described antibody under conditions that allow for the formation of antibody-antigen complexes. The antibody-antigen complexes are then detected. The presence of the complexes indicates the presence of the polypeptide.

[0040] The invention also provides a method of treating a subject suffering from, at risk for, or suspected of, suffering from a pathology ascribed to the presence of a sequence polymorphism in a subject, e.g., a human, non-human primate, cat, dog, rat, mouse, cow, pig, goat, or rabbit. The method includes providing a subject suffering from a pathology associated with aberrant expression of a first nucleic acid comprising a polymorphic sequence shown in Table 1, or its complement, and treating the subject by administering to the subject an effective dose of a therapeutic agent. Aberrant expression can include qualitative alterations in expression of a gene, e.g., expression of a gene encoding a polypeptide having an altered amino acid sequence with respect to its wild-type counterpart. Qualitatively different polypeptides can include, shorter, longer, or altered polypeptides relative to the amino acid sequence of the wild-type polypeptide. Aberrant expression can also include quantitative alterations in expression of a gene. Examples of quantitative alterations in gene expression include lower or higher levels of expression of the gene relative to its wild-type counterpart, or alterations in the temporal or tissue-specific expression pattern of a gene. Finally, aberrant expression may also include a combination of qualitative and quantitative alterations in gene expression.

[0041] The therapeutic agent can include, e.g., second nucleic acid comprising the polymorphic sequence, provided that the second nucleic acid comprises the nucleotide present in the wild type allele. In some embodiments, the second nucleic acid sequence comprises a polymorphic sequence which includes nucleotide listed in Table 1, column 5 for the polymorphic sequence.

[0042] Alternatively, the therapeutic agent can be a polypeptide encoded by a polynucleotide comprising polymorphic sequence shown in Table 1, or by a polynucleotide comprising a nucleotide sequence that is complementary to any one of the polymorphic sequences, provided that the polymorphic sequence includes the nucleotide listed in Table 1, column 6 for the polymorphic sequence.

[0043] The therapeutic agent may further include an antibody as herein described, or an oligonucleotide comprising a polymorphic sequence shown in Table 1, or by a polynucleotide comprising a nucleotide sequence that is complementary to any one the polymorphic sequences, provided that the polymorphic sequence includes the nucleotide listed in Table 1, column 6 for the polymorphic sequence,

[0044] In another aspect, the invention provides an oligonucleotide array comprising one or more oligonucleotides hybridizing to a first polynucleotide at a polymorphic site encompassed therein. The first polynucleotide can be, e.g., a nucleotide sequence comprising one or more polymorphic sequences shown in Table 1; a nucleotide sequence that is a fragment of any of the nucleotide sequence, provided that the fragment includes a polymorphic site in the polymorphic sequence; a complementary nucleotide sequence comprising a sequence complementary to one or more of the polymorphic sequences; or a nucleotide sequence that is a fragment of the complementary sequence, provided that the fragment includes a polymorphic site in the polymorphic sequence.

[0045] In preferred embodiments, the array comprises 10; 100; 1,000; 10,000; 100,000 or more oligonucleotides.

[0046] The invention also provides a kit comprising one or more of the herein-described nucleic acids. The kit can include, e.g., polynucleotide which includes one or more of the SNPs described herein. The polynucleotide can be, e.g., a nucleotide sequence which includes one or more of the polymorphic sequences shown in Table 1, and which includes a polymorphic sequence, or a fragment of the polymorphic sequence, as long as it includes the polymorphic site. The polynucleotide may alternatively contain a nucleotide sequence which includes a sequence complementary to one or more of the sequences, or a fragment of the complementary nucleotide sequence, provided that the fragment includes a polymorphic site in the polymorphic sequence.

[0047] Alternatively, or in addition, the kit can include the invention provides an isolated allele-specific oligonucleotide that hybridizes to a first polynucleotide containing a polymorphic site. The first polynucleotide can be, e.g., a nucleotide sequence comprising one or more polymorphic sequences shown in Table 1, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for the polymorphic sequence. Alternatively, the first polynucleotide can be a nucleotide sequence that is a fragment of the polymorphic sequence, provided that the fragment includes a polymorphic site in the polymorphic sequence, or a complementary nucleotide sequence which includes a sequence complementary to one or more polymorphic sequences shown in Table 1, provided that the complementary nucleotide sequence includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 6. The first polynucleotide may in addition include a nucleotide sequence that is a fragment of the complementary sequence, provided that the fragment includes a polymorphic site in the polymorphic sequence.

BRIEF DESCRIPTION OF THE DRAWING

[0048]FIG. 1 illustrates an example of the way in which SNP sites were identified in the present invention.

[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0050] Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

[0051] The invention provides human SNPs in sequences which are transcribed, i.e., are cSNPs. Many SNPs have been identified in genes related to polypeptides of known function. If desired, SNPs associated with various polypeptides can be used together. For example, SNPs can be grouped according to whether they are derived from a nucleic acid encoding a polypeptide related to particular protein family or involved in a particular function. Similarly, SNPs can be grouped according to the functions played by their gene products. Such functions include, structural proteins, proteins from which associated with metabolic pathways fatty acid metabolism, glycolysis, intermediary metabolism, calcium metabolism, proteases, and amino acid metabolism, etc. Specifically, the present invention provides a large number of human cSNP's based on at least one gene product that has not been previously identified. In contrast, and as defined specifically in the following paragraph, the cSNP's involve nucleic acid sequences that are assembled from at least one known sequence.

[0052] The present invention describes 651 distinct polymorphic sites, which are summarized in Table 1. Raw traces underlying sequence data were drawn from public databases and from the proprietary database of the Assignee of the present invention. The sequences were obtained by calling the bases from these traces, and included assigning “Phred” quality scores for each called base. For each allelic set, at the polynucleotide level, four or more nucleotide sequences were identified having at least partial overlap with one another.

[0053] As illustrated in FIG. 1, these four or more sequences could be clustered and assembled to make a consensus contig that included an ORF. In this way, the inventors found that the assembled contigs defined associated sets of two, or possibly more than two, alleles defined by a SNP at a particular polymorphic site. In order to be confirmed as a SNP site, the nucleotide change from the consensus sequence had to occur in at least two individual sequences, and had to have a “Phred” score of 23 or higher at the site of the presumed SNP. Furthermore, in a window of 5 bases on either side of the SNP, no more than 50% mismatching with the consensus sequence was allowed. In the assembly leading to each of the contigs defining the allelic set, the SNP alleles occur in polynucleotides found in public databases.

[0054] It was found that the assembled contigs defined associated sets of two, or possibly more than two, alleles defined by an SNP at a particular polymorphic site. These associations were not previously known.

[0055] At the level of translation of an ORF contained in the contigs, allelic sets were identified in which one allele defines a known polypeptide sequence that includes the polymorphic site and another polypeptide allele is not previously known. Then, various associations of alleles are possible. For example, it is possible that an allelic pair is defined in a noncoding region of the contig containing an ORF. In such cases the inventors believe that the invention resides in the recognition of the allelic pair; this association has not heretofore been made.

[0056] Alternatively, sets of allelic contigs may exist in which the polymorphic site is within an ORF, but does not result in an amino acid change among the allelic polypeptides. Thus, in another embodiment, the polymorphic site resides within an ORF and results in an amino acid change, or a frameshift, among the alleles of the allelic set. In the sets of gene products that fall within this group, at least one of the alleles at the polypeptide level is a known protein. At least one of the remaining allele or alleles in the set, carrying a variant amino acid at the polymorphic site, is a novel polypeptide not heretofore known. The invention resides at least in the recognition of the polymorphic allele as being a variant of the known reference polypeptide.

[0057] Table 1 provides information concerning the allelic sequences. One of the sequences may be termed a reference polymorphic sequence, and the corresponding second sequence includes the variant SNP at the polymorphic site. Since the reference polypeptide sequence is already known, the Sequence Listing accompanying this application provides only the sequence of the polymorphic allele, while its SEQ ID NO is provided in the Table. A reference to the SEQ ID NO that corresponds to the translated amino acid sequence is also given. The Table includes thirteen columns that provide descriptive information for each cSNP, each of which occupies one row in the Table. The column headings, and a description of each, are given below.

[0058] SNPs disclosed in Table 1 were detected by aligning large numbers of sequences from genetically diverse sources of publicly available mRNA libraries (Clontech). Software designed specifically to look for multiple examples of variant bases differing from a consensus sequence was created and deployed. A criteria of a minimum of 2 occurrences of a sequence differing from the consensus in high quality sequence reads was used to identify an SNP.

[0059] The SNPs described herein may be useful in diagnostic kits, for DNA arrays on chips and for other uses that involve hybridization of the SNP.

[0060] Specific SNPs may have utility where a disease has already been associated with that gene. Examples of possible disease correlations between the claimed SNPs with members of the genes of each classification are listed below:

[0061] Amylases

[0062] Amylase is responsible for endohydrolysis of 1,4-alpha-glucosidic linkages in oligosaccharides and polysaccharides. Variations in amylase gene may be indicative of delayed maturation and of various amylase producing neoplasms and carcinomas.

[0063] Amyloid

[0064] The serum amyloid A (SAA) proteins comprise a family of vertebrate proteins that associate predominantly with high density lipoproteins (HDL). The synthesis of certain members of the family is greatly increased in inflammation. Prolonged elevation of plasma SAA levels, as in chronic inflammation, 15 results in a pathological condition, called amyloidosis, which affects the liver, kidney and spleen and which is characterized by the highly insoluble accumulation of SAA in these tissues. Amyloid selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism. Deposition of fibrillar amyloid proteins intraneuronally, as neurofibrillary tangles, extracellularly, as plaques and in blood vessels, is characteristic of both Alzheimer's disease and aged Down's syndrome. Amyloid deposition is also associated with type II diabetes mellitus.

[0065] Angiopoeitin

[0066] Members of the angiopoeitin/fibrinogen family have been shown to stimulate the generation of new blood vessels, inhibit the generation of new blood vessels, and perform several roles in blood clotting. This generation of new blood vessels, called angiogenesis, is also an essential step in tumor growth in order for the tumor to get the blood supply it needs to expand. Variation in these genes may be predictive of any form of heart disease, numerous blood clotting disorders, stroke, hypertension and predisposition to tumor formation and metastasis. In particular, these variants may be predictive of the response to various antihypertensive drugs and chemotherapeutic and anti-tumor agents.

[0067] Apoptosis-Related Proteins

[0068] Active cell suicide (apoptosis) is induced by events such as growth factor withdrawal and toxins. It is controlled by regulators, which have either an inhibitory effect on programmed cell death (anti-apoptotic) or block the protective effect of inhibitors (pro-apoptotic). Many viruses have found a way of countering defensive apoptosis by encoding their own anti-apoptosis genes preventing their target-cells from dying too soon. Variants of apoptosis related genes may be useful in formulation of anti-aging drugs.

[0069] Cadherin, Cyclin, Polymerase, Oncogenes, Histones, Kinases

[0070] Members of the cell division/cell cycle pathways such as cyclins, many transcription factors and kinases, DNA polymerases, histones, helicases and other oncogenes play a critical role in carcinogenesis where the uncontrolled proliferation of cells leads to tumor formation and eventually metastasis. Variation in these genes may be predictive of predisposition to any form of cancer, from increased risk of tumor formation to increased rate of metastasis. In particular, these variants may be predictive of the response to various chemotherapeutic and anti-tumor agents.

[0071] Colony-Stimulating Factor-Related Proteins

[0072] Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages.

[0073] Complement-Related Proteins

[0074] Complement proteins are immune associated cytotoxic agents, acting in a chain reaction to exterminate target cells to that were opsonized (primed) with antibodies, by forming a membrane attack complex (MAC). The mechanism of killing is by opening pores in the target cell membrane. Variations in 20 complement genes or their inhibitors are associated with many autoimmune disorders. Modified serum levels of complement products cause edemas of various tissues, lupus (SLE), vasculitis, glomerulonephritis, renal failure, hemolytic anemia, thrombocytopenia, and arthritis. They interfere with mechanisms of ADCC (antibody dependent cell cytotoxicity), severely impair immune competence and reduce phagocytic ability. Variants of complement genes may also be indicative of type I diabetes mellitus, meningitis neurological disorders such as Nemaline myopathy, Neonatal hypotonia, muscular disorders such as congenital myopathy and other diseases.

[0075] Cytochrome

[0076] The respiratory chain is a key biochemical pathway which is essential to all aerobic cells. There are five different cytochromes involved in the chain. These are heme bound proteins which serve as electron carriers. Modifications in these genes may be predictive of ataxia areflexia, dementia and myopathic and neuropathic changes in muscles. Also, association with various types of solid tumors.

[0077] Kinesins

[0078] Kinesins are tubulin molecular motors that function to transport organelles within cells and to move chromosomes along microtubules during cell division. Modifications of these genes may be indicative of neurological disorders such as Pick disease of the brain, tuberous sclerosis.

[0079] Cytokines, Interferon, Interleukin

[0080] Members of the cytokine families are known for their potent ability to stimulate cell growth and division even at low concentrations. Cytokines such as erythropoietin are cell-specific in their growth stimulation; erythropoietin is useful for the stimulation of the proliferation of erythroblasts. Variants in cytokines may be predictive for a wide variety of diseases, including cancer predisposition.

[0081] G-Protein Coupled Receptors

[0082] G-protein coupled receptors (also called R7G) are an extensive group of hormones, neurotransmitters, odorants and light receptors which transduce extracellular signals by interaction with guanine nucleotide-binding (G) proteins. Alterations in genes coding for G-coupled proteins may be involved in and indicative of a vast number of physiological conditions. These include blood pressure regulation, renal dysfunctions, male infertility, dopamine associated cognitive, emotional, and endocrine functions, hypercalcemia, chondrodysplasia and osteoporosis, pseudohypoparathyroidism, growth retardation and dwarfism.

[0083] Thioesterases

[0084] Eukaryotic thiol proteases are a family of proteolytic enzymes which contain an active site cysteine. Catalysis proceeds through a thioester intermediate and is facilitated by a nearby histidine side chain; an asparagine completes the essential catalytic triad. Variants of thioester associated genes may be predictive of neuronal disorders and mental illnesses such as Ceroid Lipoffiscinosis, Neuronal 1, Infantile, Santavuori disease and more.

[0085] Breakdown Classifications of SNPS

[0086] The following list describes the numerical breakdown by molecule type of the SNPs described in Table 1. The key to these molecule types is as follows. TPase_associated: 864 Guanylyl: 3 MHC: 1077 amylase: 44 amylaseinhib: 1 amyloid: 96 apoptosis: 91 apoptosisinhib: 29 apoptosisrecep: 14 biotindep: 29 cadhenn: 415 calcium_channel: 85 carboxylase: 4 cathepsin: 336 cathepsininhib: 41 chloride_channel: 90 collagen: 1542 complement: 222 complementinhib: 21 complementrecept: 10 csf: 31 csf recept: 37 cyclin: 65 cyto450: 136 cytochrome: 659 deaminase: 44 dehydrogenase: 1235 desaturase: 9 dna_rna_bind: 1309 dna_rna_bind_inhib: 16 dynein: 108 elastase: 134 elastaseinhib: 6 eph: 487 esterase: 258 esteraseinhib: 3 fgf: 34 fgf receptor: 12 gaba: 45 glucoamylase: 106 glucuronidase: 14 glycoprotein: 3176 helicase: 333 histone: 272 homeobox: 431 hydrolase: 187 hydroxysteroid: 84 hypoxanthine: 4 immunoglob: 1106 immunoglob_recept: 19 interferon: 322 interleukin: 88 interleukinrecept: 126 isomerase: 404 isomeraseinhibitor: 45 isomerasereceptor: 4 kinase: 1684 kinase inhibitor: 187 kinase receptor: 233 kinesin: 86 laminin: 196 lipase: 63 metallothionein: 62 misc_channel: 215 ngf: 30 nucl_recpt: 339 nuclease: 298 oncogene: 783 oxidase: 128 oxygenase: 14 peptidase: 150 peroxidase: 115 phosphatase: 668 phosphataseinhib: 71 phosphorylase: 84 polymerase: 489 potassium_channel: 43 prostaglandin: 55 protease: 954 proteaseinhib: 271 reductase: 243 ribosomal prot: 1040 struct: 3128 sulfotransferase: 42 synthase: 893 tgf: 117 tgfreceptor: 41 thioesterase: 3 thiolase: 38 tm7: 453 tnf: 151 tnfreceptor: 36 traffic: 22 transcriptfactor: 1139 transferase: 291 transport: 900 tubulin: 334 ubiquitin: 229 water_channel: 18 unclassified: 10567

[0087] TABLE 1 The key to the molecule type is as follows: Abbrev: Title: amylase amylase protein amylaseinhib amylase inhibitor amyloid amyloid protein apoptosis apoptosis associated protein apoptosisinhib apoptosis inhibitors apoptosisrecep apoptosis receptors ATPase_associated ATPase associated protein biotindep biotin dependent enzyme/protein cadherin cadherin protein calcium_channel calcium channel protein carboxylase carboxylase protein cathepsin cathepsin/carboxypeptidases cathepsininhib cathepsin/carboxypeptidase inhibitor chloride_channel chloride channel protein collagen collagen complement complement protein complementrecept complement receptor protein complementinhib complement inhibitor csf colony stimulating factor csfrecept colony stimulating factor receptor cyclin cyclin protein cyto450 cytochrome p450 protein cytochrome cytochrome related protein deaminase deaminase dehydrogenase dehydrogenase desaturase desaturase dna_rna_bind DNA/RNA binding protein/factor dna_rna_inhib DNA/RNA binding protein/factor inhibitor dynein dynein elastase elastase elastaseinhib elastase inhibitor eph EPH family of tyrosine kinases esterase esterase esteraseinhib esterase inhibitor fgf fibroblast growth factor fgfreceptor fibroblast growth factor receptor gaba GABA receptor glucoamylase glucoamylase glucoronidase glucoronidase glycoprotein glycoprotein Guanylyl guanylylate cyclase helicase helicase histone histone HOM homologous homeobox homeobox protein hydrolase hydrolase hydroxysteroid hydroxysteroid associated protein hypoxanthine hypoxanthine associated protein immunoglob immunoglobulin immunoglobrecept immunoglobulin receptor interferon interferon interleukin interleukin interleukinrecept interleukin receptor isomerase isomerase isomeraseinhibitor isomerase inhibitor isomerasereceptor isomerase receptor kinase kinase kinaseinhibitor kinase inhibitor kinasereceptor kinase receptor kinesin kinesin laminin laminin associated protein lipase lipase metallothionein metallothionein MHC major histocompatability complex misc_channel miscellaneous channel ngf nerve growth factor nuci_recpt nuclear receptor nuclease nuclease oncogene oncogene associated protein oxidase oxidase oxygenase oxygenase peptidase peptidase peroxidase peroxidase phosphatase phosphatase phosphataseinhib phosphatase inhibitor phosphorylase phosphorylase PIR PIR DATABASE (release 56, 29- OCT-1998) polymerase polymerase potassium_channel potassium channel protein prostaglandin prostaglandin protease protease proteaseinhib protease inhibitor reductase reductase ribosomalprot ribosomal associated protein RTR EMBLDATABASE translated entries not to be incorporated into SWISS-PROT (20-JUL-1998) SIM similar SPTR EMBL DATABASE translated entries to be incorporated into SWISS-PROT (20-JUL-1998) struct structural associated protein sulfotransferase sulfotransferase SWP SWISS-PROT DATABASE (release 18-OCT-1998) SWPN SWISS-PROT Update (release 11- NOV-98) synthase synthase tgf transforming growth factor tgfreceptor transforming growth factor receptor thioesterase thioesterase thiolase thiolase tm7 seven transmembrane domain G- protein coupled receptor tnf necrosis factor receptor traffic tumor necrosis factor tnfreceptor tumor trafficking associated protein TRN EMBL DATABASE translated entries update (20-JUL-1998) transcriptfactor transcription factor transferase transferase transport transport protein tubulin tubulin ubiquitin ubiquitin unclassified Protein not categorized into one of the aforementioned protein families water channel water channel protein

[0088] A compilation of polymorphisms is listed in Table 1. Table 1 includes thirteen columns that provide descriptive information for each cSNP, each of which occupies one row in the Table. The column headings, and an explanation for each, are given below.

[0089] The first column of the table lists the names assigned to the fragments in which the polymorphisms occur. The fragments are all human genomic fragments. The sequence of one allelic form of each of the fragments (arbitrarily referred to as the prototypical or reference form ) has been previously published. These sequences are listed at http://www-genome.wi.mit.edu/ (all STS's sequence tag sites)); http://shgc.stanford.edu (Stanford STS's); and http://www.tigr.org/ (TIGR STS's). The web sites also list primers for amplification of the fragments, and the genomic location of the fragments. Some fragments arc expressed sequence tags, and some are random genomic fragments. All information in the web sites concerning the fragments listed in the table is incorporated by reference in its entirety for all purposes.

[0090] The second column lists the position in the fragment in which a polymorphic site has been found. Positions are numbered consecutively with the first base of the fragment sequence listed as in one of the above databases being assigned the number one. The third column lists the base occupying the polymorphic site in the sequence in the data base. This base is arbitrarily designated the reference or prototypical form, but it is not necessarily the most frequently occurring form. The fourth column in the table lists the alternative base(s) at the polymorphic site. The fifth column of the table lists a 5′ (upstream or forward) primer that hybridizes with the 5′ end of the DNA sequence to be amplified. The sixth column of the table lists a 3′ (downstream or reverse) primer that hybridizes with the complement of the 3′ end of the sequence to be amplified. The seventh column of the table lists a number of bases of sequence on either side of the polymorphic site in each fragment. The indicated sequences can either be DNA or RNA. In the latter, the T's shown in the table are replaced by U's. The base occupying the polymorphic site is indicated in EUT′AC-IUB ambiguity code.

[0091] “SEQ ID” provides the cross-references to the two nucleotide SEQ ID NOS: for the cognate pair, which are numbered consecutively, and, as explained below, amino acid SEQ ID NOS: as well, in the Sequence Listing of the application.

[0092] Each sequence entry in the Sequence Listing also includes a cross-reference to the CuraGen sequence ID, under the label “Accession number”. The first pair of SEQ ID NOS: given in the first column of each row of the Table is the SEQ ID NO: identifying the nucleic acid sequence for the polymorphism. If a polymorphism carries an entry for the amino acid portion of the row, a third SEQ ID NO: appears in parentheses in the column “Amino acid before” (see below) for the reference amino acid sequence, and a fourth SEQ ID NO: appears in parentheses in the column “Amino acid after” (see below) for the polymorphic amino acid sequence. The latter SEQ ID NOS: refer to amino acid sequences giving the cognate reference and polymorphic amino acid sequences that are the translation of the nucleotide polymorphism. If a polymorphism carries no entry for the protein portion of the row, only one pair SEQ ID NOS: is provided, in the first column.

[0093] “CuraGen sequence ID” provides CuraGen Corporation's accession number.

[0094] “Base pos. of SNP” gives the numerical position of the nucleotide in the nucleic acid at which the cSNP is found, as identified in this invention.

[0095] “Polymorphic sequence” provides a 51-base sequence with the polymorphic site at the 26^(th) base in the sequence, as well as 25 bases from the reference sequence on the 5′ side and the 3′ side of the polymorphic site. The designation at the polymorphic site is enclosed in square brackets, and provides first, the reference nucleotide; second, a “slash (/)”; and third, the polymorphic nucleotide. In certain cases the polymorphism is an insertion or a deletion. In that case, the position that is “unfilled” (i.e., the reference or the polymorphic position) is indicated by the word “gap”.

[0096] “Base before” provides the nucleotide present in the reference sequence at the position at which the polymorphism is found.

[0097] “Base after” provides the altered nucleotide at the position of the polymorphism.

[0098] “Amino acid before” provides the amino acid in the reference protein, if the polymorphism occurs in a coding region. This column also includes the SEQ ID NO: in parentheses for the translated reference amino acid sequence if the polymorphism occurs in a coding region.

[0099] “Amino acid after” provides the amino acid in the polymorphic protein, if the polymorphism occurs in a coding region. This column also includes the SEQ ID NO in parentheses for the translated polymorphic amino acid sequence if the polymorphism occurs in a coding region.

[0100] “Type of change” provides information on the nature of the polymorphism. “SILENT-NONCODING” is used if the polymorphism occurs in a noncoding region of a nucleic acid. “SILENT-CODING” is used if the polymorphism occurs in a coding region of a nucleic acid of a nucleic acid and results in no change of amino acid in the translated polymorphic protein. “CONSERVATIVE” is used if the polymorphism occurs in a coding region of a nucleic acid and provides a change in which the altered amino acid falls in the same class as the reference amino acid. The classes are: 1) Aliphatic: Gly, Ala, Val, Leu, Ile; 2) Aromatic: Phe, Tyr, Trp; 3) Sulfur-containing: Cys, Met; 4) Aliphatic OH: Ser, Thr; 5) Basic: Lys, Arg, His; 6) Acidic: Asp, Glu, Asn, Gln; 7) Pro falls in none of the other classes; and 8) End defines a termination codon.

[0101] “NONCONSERVATIVE” is used if the polymorphism occurs in a coding region of a nucleic acid and provides a change in which the altered amino acid falls in a different class than the reference amino acid.

[0102] “FRAMESHIFT” relates to an insertion or a deletion. If the frameshift occurs in a coding region, the Table provides the translation of the frameshifted codons 3′ to the polymorphic site.

[0103] “Protein classification of CuraGen gene” provides a generic class into which the protein is classified. Multiple classes of proteins were identified as listed above in the discussion of Table 1.

[0104] “Name of protein identified following a BLASTX analysis of the CuraGen sequence” provides the database reference for the protein found to resemble the novel reference-polymorphism cognate pair most closely.

[0105] “Similarity (pvalue) following a BLASTX analysis” provides the pvalue, a statistical measure from the BLASTX analysis that the polymorphic sequence is similar to, and therefore an allele of, the reference, or wild-type, sequence. In the present application, a cutoff of pvalue>1×10⁻⁵⁰ (entered, for example, as 1.0E-50 in the Table) is used to establish that the reference-polymorphic cognate pairs are novel. A pvalue<1×10⁻⁵⁰ defines proteins considered to be already known.

[0106] “Map location” provides any information available at the time of filing related to localization of a gene on a chromosome.

[0107] The polymorphisms are arranged in Table 1 in the following order:

[0108] SEQ ID NOs: 1-422 are nucleotide sequences for SNPs that are silent.

[0109] SEQ ID NOs: 423-480 are nucleotide sequences for SNPs that lead to conservative amino acid changes.

[0110] SEQ ID NOs: 481-619 are nucleotide sequences for SNPs that lead to nonconservative amino acid changes.

[0111] SEQ ID NOs: 620-651 are nucleotide sequences for SNPs that involve a gap. With respect to the reference or wild-type sequence at the position of the polymorphism, the allelic cSNP introduces an additional nucleotide (an insertion) or deletes a nucleotide (a deletion). An SNP that involves a gap generates a frame shift.

[0112] Also presented in the sequence listing filed herewith are predicted amino acid sequences encoded by the polymorphic sequences shown in Table 1.

[0113] SEQ ID NOs: 652-709 are the amino acid sequences centered at the polymorphic amino acid residue for the protein products provided by SNPs that lead to conservative amino acid changes. 7 or 8 amino acids on either side of the polymorphic site are shown. The order in which these sequences appear mirrors the order of presentation of the cognate nucleotide sequences, and is set forth in the Table.

[0114] SEQ ID NOs: 710-848 are the amino acid sequences centered at the polymorphic amino acid residue for the protein products provided by SNPs that lead to nonconservative amino acid changes. 7 or 8 amino acids on either side of the polymorphic site are shown. The order in which these sequences appear mirrors the order of presentation of the cognate nucleotide sequences, and is set forth in the Table.

[0115] SEQ ID NOs: 849-880 are the amino acid sequences centered at the polymorphic amino acid residue for the protein products provided by SNPs that lead to frameshift-induced amino acid changes. 7 or 8 amino acids on either side of the polymorphic site are shown. The order in which these sequences appear mirrors the order of presentation of the cognate nucleotide sequences, and is set forth in the Table.

[0116] Provided herein are compositions which include, or are capable of detecting, nucleic acid sequences having these polymorphisms, as well as methods of using nucleic acids.

[0117] Identification of Individuals Carrying SNPs

[0118] Individuals carrying polymorphic alleles of the invention may be detected at either the DNA, the RNA, or the protein level using a variety of techniques that are well known in the art. Strategies for identification and detection are described in e.g., EP 730,663, EP 717,113, and PCT US97/02102. The present methods usually employ pre-characterized polymorphisms. That is, the genotyping location and nature of polymorphic forms present at a site have already been determined. The availability of this information allows sets of probes to be designed for specific identification of the known polymorphic forms.

[0119] Many of the methods described below require amplification of DNA from target samples. This can be accomplished by e.g., PCR. (1989), B. for detecting polymorphisms. See generally PCR Technology: Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991); Eckert et al., PCR Methods and Applications 1, 17 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202.

[0120] The phrase “recombinant protein” or “recombinantly produced protein” refers to a peptide or protein produced using non-native cells that do not have an endogenous copy of DNA able to express the protein. In particular, as used herein, a recombinantly produced protein relates to the gene product of a polymorphic allele, i.e., a “polymorphic protein” containing an altered amino acid at the site of translation of the nucleotide polymorphism. The cells produce the protein because they have been genetically altered by the introduction of the appropriate nucleic acid sequence. The recombinant protein will not be found in association with proteins and other subcellular components normally associated with the cells producing the protein. The terms “protein” and “polypeptide” are used interchangeably herein.

[0121] The phrase “substantially purified” or “isolated” when referring to a nucleic acid, peptide or protein, means that the chemical composition is in a milieu containing fewer, or preferably, essentially none, of other cellular components with which it is naturally associated. Thus, the phrase “isolated” or “substantially pure” refers to nucleic acid preparations that lack at least one protein or nucleic acid normally associated with the nucleic acid in a host cell. It is preferably in a homogeneous state although it can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as gel electrophoresis or high performance liquid chromatography. Generally, a substantially purified or isolated nucleic acid or protein will comprise more than 80% of all macromolecular species present in the preparation. Preferably, the nucleic acid or protein is purified to represent greater than 90% of all macromolecular species present. More preferably the nucleic acid or protein is purified to greater than 95%, and most preferably the nucleic acid or protein is purified to essential homogeneity, wherein other macromolecular species are not detected by conventional analytical procedures.

[0122] The genomic DNA used for the diagnosis may be obtained from any nucleated cells of the body, such as those present in peripheral blood, urine, saliva, buccal samples, surgical specimen, and autopsy specimens. The DNA may be used directly or may be amplified enzymatically in vitro through use of PCR (Saiki et al. Science 239:487-491 (1988)) or other in vitro amplification methods such as the ligase chain reaction (LCR) (Wu and Wallace Genomics 4:560-569 (1989)), strand displacement amplification (SDA) (Walker et al. Proc. Natl. Acad. Sci. U.S.A. 89:392-396 (1992)), self-sustained sequence replication (3SR) (Fahy et al. PCR Methods P&J& 1:25-33 (1992)), prior to mutation analysis.

[0123] The method for preparing nucleic acids in a form that is suitable for mutation detection is well known in the art. A “nucleic acid” is a deoxyribonucleotide or ribonucleotide polymer in either single-or double-stranded form, including known analogs of natural nucleotides unless otherwise indicated. The term “nucleic acids”, as used herein, refers to either DNA or RNA. “Nucleic acid sequence” or “polynucleotide sequence” refers to a single-stranded sequence of deoxyribonucleotide or ribonucleotide bases read from the 5′ end to the 3′ end. The direction of 5′ to 3′ addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are beyond the 5′ end of the RNA transcript in the 5′ direction are referred to as “upstream sequences”; sequence regions on the DNA strand having the same sequence as the RNA and which are beyond the 3′ end of the RNA transcript in the 3′ direction are referred to as “downstream sequences”. The term includes both self-replicating plasmids, infectious polymers of DNA or RNA and nonfunctional DNA or RNA. The complement of any nucleic acid sequence of the invention is understood to be included in the definition of that sequence. “Nucleic acid probes” may be DNA or RNA fragments.

[0124] The detection of polymorphisms in specific DNA sequences, can be accomplished by a variety of methods including, but not limited to, restriction-fragment-length-polymorphism detection based on allele-specific restriction-endonuclease cleavage (Kan and Dozy Lancet ii:910-912 (1978)), hybridization with allele-specific oligonucleotide probes (Wallace et al. Nucl. Acids Res. 6:3543-3557 (1978)), including immobilized oligonucleotides (Saiki et al. Proc. Natl. Acad. SCI. USA 86:6230-6234 (1969)) or oligonucleotide arrays (Maskos and Southern Nucl. Acids Res 21:2269-2270 (1993)), allele-specific PCR (Newton et al. Nucl Acids Res 17:2503-2516 (1989)), mismatch-repair detection (MRD) (Faham and Cox Genome Res 5:474-482 (1995)), binding of MutS protein (Wagner et al. Nucl Acids Res 23:3944-3948 (1995), denaturing-gradient gel electrophoresis (DGGE) (Fisher and Lerman et al. Proc. Natl. Acad. Sci. U.S.A. 80:1579-1583 (1983)), single-strand-conformation-polymorphism detection (Orita et al. Genomics 5:874-879 (1983)), RNAase cleavage at mismatched base-pairs (Myers et al. Science 230:1242 (1985)), chemical (Cotton et al. Proc. Natl. w Sci. U.S.A, 8Z4397-4401(1988)) or enzymatic (Youil et al. Proc. Natl. Acad. Sci. U.S.A. 92:87-91 (1995)) cleavage of heteroduplex DNA, methods based on allele specific primer extension (Syvanen et al. Genomics 8:684-692 (1990)), genetic bit analysis (GBA) (Nikiforov et al. &&I Acids 22:4167-4175 (1994)), the oligonucleotide-ligation assay (OLA) (Landegren et al. Science_(—)241:1077 (1988)), the allele-specific ligation chain reaction (LCR) (Barrany Proc. Natl. Acad. Sci. U.S.A. 88:189-1 93 (1991)), gap-LCR (Abravaya et al. Nucl Acids Res 23:675-682 (1995)), radioactive and/or fluorescent DNA sequencing using standard procedures well known in the art, and peptide nucleic acid (PNA) assays (Orum et al., Nucl. Acids Res, 21:5332-5356 (1993); Thiede et al., Nucl. Acids Res. 24:983-984 (1996)).

[0125] “Specific hybridization” or “selective hybridization” refers to the binding, or duplexing, of a nucleic acid molecule only to a second particular nucleotide sequence to which the nucleic acid is complementary, under suitably stringent conditions when that sequence is present in a complex mixture (e.g., total cellular DNA or RNA). “Stringent conditions” are conditions under which a probe will hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and are different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter ones. Generally, stringent conditions are selected such that the temperature is about 5° C. lower than the thermal melting point (Tm) for the specific sequence to which hybridization is intended to occur at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the target sequence hybridizes to the complementary probe at equilibrium. Typically, stringent conditions include a salt concentration of at least about 0.01 to about 1.0 M Na ion concentration (or other salts), at pH 7.0 to 8.3. The temperature is at least about 30° C. for short probes (e.g., 10 to 50 nucleotides). Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. For example, conditions of 5×SSPE (750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-30° C. are suitable for allele-specific probe hybridizations.

[0126] “Complementary” or “target” nucleic acid sequences refer to those nucleic acid sequences which selectively hybridize to a nucleic acid probe. Proper annealing conditions depend, for example, upon a probe's length, base composition, and the number of mismatches and their position on the probe, and must often be determined empirically. For discussions of nucleic acid probe design and annealing conditions, see, for example, Sambrook et al., or Current Protocols in Molecular Biology, F. Ausubel et al., ed., Greene Publishing and Wiley-Interscience, New York (1987).

[0127] A perfectly matched probe has a sequence perfectly complementary to a particular target sequence. The test probe is typically perfectly complementary to a portion of the target sequence. A “polymorphic” marker or site is the locus at which a sequence difference occurs with respect to a reference sequence. Polymorphic markers include restriction fragment length polymorphisms, variable number of tandem repeats (VNTR's), hypervariable regions, minisatellites, dinucleotide repeats. trinucleotide repeats, tetranucleotide repeats, simple sequence repeats, and insertion elements such as Alu. The reference allelic form may be, for example, the most abundant form in a population, or the first allelic form to be identified, and other allelic forms are designated as alternative, variant or polymorphic alleles. The allelic form occurring most frequently in a selected population is sometimes referred to as the “wild type” form, and herein may also be referred to as the “reference” form. Diploid organisms may be homozygous or heterozygous for allelic forms. A diallelic polymorphism has two distinguishable forms (i.e., base sequences), and a triallelic polymorphism has three such forms.

[0128] As use herein an “oligonucleotide” is a single-stranded nucleic acid ranging in length from 2 to about 60 bases. Oligonucleotides are often synthetic but can also be produced from naturally occurring polynucleotides. A probe is an oligonucleotide capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing via hydrogen bond formation. Oligonucleotides probes are often between 5 and 60 bases, and, in specific embodiments, may be between 1040, or 15-30 bases long. An oligonucleotide probe may include natural (i.e. A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in an oligonucleotide probe may be joined by a linkage other than a phosphodiester bond, such as a phosphoramidite linkage or a phosphorothioate linkage, or they may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than by phosphodiester bonds, so long as it does not interfere with hybridization. Examples of an oligonucleotide are shown in Table 1. Oligonucleotides can be all of a nucleic acid segment as represented in column 4 of Table 1; a nucleic acid sequence which comprises a nucleic acid segment represented in column 4 of Table 1 and additional nucleic acids (present at either or both ends of a nucleic acid segment of column 4); or a portion (fragment) of a nucleic acid segment represented in column 4 of the table which includes a polymorphic site. Preferred polymorphic sites of the invention include segments of DNA or their complements, which include any one of the polymorphic sites shown in the Table. The segments can be between 5 and 250 bases, and, in specific embodiments are between 5-10, 5-20, 10-20, 10-50, 20-50 or 10-100 bases. The polymorphic site can occur within any position of the segment. The segments can be from any of the allelic forms of the DNA shown in the Table.

[0129] As used herein, the term “primer” refers to a single-stranded oligonucleotide which acts as a point of initiation of template-directed DNA synthesis under appropriate conditions (e.g., in the presence of four different nucleoside triphosphates and a polymerization agent, such as DNA polymerase, RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature. The appropriate length of a primer depends on the intended use of the primer, but typically ranges from 15 to 30 nucleotides. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. A primer need not be perfectly complementary to the exact sequence of the template, but should be sufficiently complementary to hybridize with it. The term “primer site” refers to the sequence of the target DNA to which a primer hybridizes. The term “primer pair” refers to a set of primers including a 5′ (upstream) primer that hybridizes with the 5′ end of the DNA sequence to be amplified and a 3′ (downstream) primer that hybridizes with the complement of the 3′ end of the sequence to be amplified.

[0130] DNA fragments can be prepared, for example, by digesting plasmid DNA, or by use of PCR. Oligonucleotides for use as primers or probes are chemically synthesized by methods known in the field of the chemical synthesis of polynucleotides, including by way of non-limiting example the phosphoramidite method described by Beaucage and Carruthers, Tetrahedron Lett 22:1859-1 862 (1981) and the triester method provided by Matteucci, et al., J. Am. Chem. Soc., 103:3185 (1981) both incorporated herein by reference. These syntheses may employ an automated synthesizer, as described in Needham-VanDevanter, D. R., et al., Nucleic Acids Res. 12:61596168 (1984). Purification of oligonucleotides may be carried out by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson, J. D. and Regnier. F. E., ,J. Chrom,, 255:137-149 (1983). A double stranded fragment may then be obtained, if desired, by annealing appropriate complementary single strands together under suitable conditions or by synthesizing the complementary strand using a DNA polymerase with an appropriate primer sequence. Where a specific sequence for a nucleic acid probe is given, it is understood that the complementary strand is also identified and included. The complementary strand will work equally well in situations where the target is a double-stranded nucleic acid.

[0131] The sequence of the synthetic oligonucleotide or of any nucleic acid fragment can be can be obtained using either the dideoxy chain termination method or the Maxam-Gilbert method (see Sambrook et al. Molecular Cloning—a Laboratory Manual (2nd Ed.), Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1989), which is incorporated herein by reference. This manual is hereinafter referred to as “Sambrook et al.”; Zyskind et al., (1988)). Recombinant DNA Laboratory Manual, (Acad. Press, New York). Oligonucleotides useful in diagnostic assays are typically at least 8 consecutive nucleotides in length, and may range upwards of 18 nucleotides in length to greater than 100 or more consecutive nucleotides.

[0132] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the SNP-containing nucleotide sequences of the invention, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, about 25, about 50, or about 60 nucleotides or an entire SNP coding strand, or to only a portion thereof.

[0133] In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a polymorphic nucleotide sequence of the invention. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence of the invention. The term “noncoding region” refers to 5′ and 3′ sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).

[0134] Given the coding strand sequences disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. For example, the antisense nucleic acid molecule can generally be complementary to the entire coding region of an mRNA, but more preferably as embodied herein, it is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of the mRNA. An antisense oligonucleotide can range in length between about 5 and about 60 nucleotides, preferably between about 10 and about 45 nucleotides, more preferably between about 15 and 40 nucleotides, and still more preferably between about 15 and 30 in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.

[0135] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0136] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a polymorphic protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementary to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

[0137] In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual -units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids Res 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res 15: 6131-6148) or a chimeric RNA -DNA analogue (Inoue et al. (1987) FEBS Lett 215: 327-330).

[0138] The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: “reference sequence”, “comparison window”, “sequence identity”, “percentage of sequence identity”, and “substantial identity”. A “reference sequence” is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing, or may comprise a complete cDNA or gene sequence. Optimal alignment of sequences for aligning a comparison window may, for example, be conducted by the local homology algorithm of Smith and Waterman Adv. AppI. Math, 2482 (1981), by the homology alignment algorithm of Needleman and Wunsch J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman Proc. Natl. Acad. Sci. U.S.A. 852444 (1988), or by computerized implementations of these algorithms (for example, GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis.).

[0139] Techniques for nucleic acid manipulation of the nucleic acid sequences harboring the cSNP's of the invention, such as subcloning nucleic acid sequences encoding polypeptides into expression vectors, labeling probes, DNA hybridization, and the like, are described generally in Sambrook et al., The phrase “nucleic acid sequence encoding” refers to a nucleic acid which directs the expression of a specific protein, peptide or amino acid sequence. The nucleic acid sequences include both the DNA strand sequence that is transcribed into RNA and the RNA sequence that is translated into protein, peptide or amino acid sequence. The nucleic acid sequences include both the full length nucleic acid sequences disclosed herein as well as non-full length sequences derived from the full length protein. It being further understood that the sequence includes the degenerate codons of the native sequence or sequences which may be introduced to provide codon preference in a specific host cell. Consequently, the principles of probe selection and array design can readily be extended to analyze more complex polymorphisms (see EP 730,663). For example, to characterize a triallelic SNP polymorphism, three groups of probes can be designed tiled on the three polymorphic forms as described above. As a further example, to analyze a diallelic polymorphism involving a deletion of a nucleotide, one can tile a first group of probes based on the undeleted polymorphic form as the reference sequence and a second group of probes based on the deleted form as the reference sequence.

[0140] For assay of genomic DNA, virtually any biological convenient tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, buccal, skin and hair can be used. Genomic DNA is typically amplified before analysis. Amplification is usually effected by PCR using primers flanking a suitable fragment e.g., of 50-500 nucleotides containing the locus of the polymorphism to be analyzed. Target is usually labeled in the course of amplification. The amplification product can be RNA or DNA, single stranded or double stranded. If double stranded, the amplification product is typically denatured before application to an array. If genomic DNA is analyzed without amplification, it may be desirable to remove RNA from the sample before applying it to the array. Such can be accomplished by digestion with DNase-free RNAase.

DETECTION OF POLYMORPHISMS IN A NUCLEIC ACID SAMPLE

[0141] The SNPs disclosed herein can be used to determine which forms of a characterized polymorphism are present in individuals under analysis.

[0142] The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., Nature 324, 163-166 (1986); Dattagupta, EP 235,726, Saiki, WO 89/11548. Allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms in the respective segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Some probes are designed to hybridize to a segment of target DNA such that the polymorphic site aligns with a central position (e.g., in a 15-mer at the 7 position; in a 16-mer, at either the 7, 8 or 9 position) of the probe. This design of probe achieves good discrimination in hybridization between different allelic forms.

[0143] Allele-specific probes are often used in pairs, one member of a pair showing a perfect match to a reference form of a target sequence and the other member showing a perfect match to a variant form. Several pairs of probes can then be immobilized on the same support for simultaneous analysis of multiple polymorphisms within the same target sequence.

[0144] The polymorphisms can also be identified by hybridization to nucleic acid arrays, some examples of which are described in oublished PCT application WO 95/11995. WO 95/11995 also describes subarrays that are optimized for detection of a variant form of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first reference sequence. The second group of probes is designed by the same principles, except that the probes exhibit complementarity to the second reference sequence. The inclusion of a second group (or further groups) can be particularly useful for analyzing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the length of the probes (e.g., two or more mutations within 9 to 21 bases).

[0145] An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. See Gibbs, Nucleic Acid Res. 17 2427-2448 (1989). This primer is used in conjunction with a second primer which hybridizes at a distal site. Amplification proceeds from the two-primers, resulting in a detectable product which indicates the particular allelic form is present. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed. The method works best when the mismatch is included in the 3′-most position of the oligonucleotide aligned with the polymorphism because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456).

[0146] Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution. Erlich, ed., PCR Technology, Principles and Applications for DNA Amplification, (W.H. Freeman and Co New York, 1992, Chapter 7).

[0147] Alleles of target sequences can be differentiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770 (1989). Amplified PCR products can be generated and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence differences between alleles of target sequences.

[0148] The genotype of an individual with respect to a pathology suspected of being caused by a genetic polymorphism may be assessed by association analysis. Phenotypic traits suitable for association analysis include diseases that have known but hitherto unmapped genetic components (e.g., agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial hypercholesterolemia, polycystic kidney disease, hereditary spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary hemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos syndrome, osteogenesis imperfecta, and acute intermittent porphyria).

[0149] Phenotypic traits also include symptoms of, or susceptibility to, multifactorial diseases of which a component is or may be genetic, such as autoimmune diseases, inflammation, cancer, system, diseases of the nervous and infection by pathogenic microorganisms. Some examples of autoimmune diseases include rheumatoid arthritis, multiple sclerosis, diabetes (insulin-dependent and non-independent), systemic lupus erythematosus and Graves disease. Some examples of cancers include cancers of the bladder, brain, breast, colon, esophagus, kidney, oral cavity, ovary, pancreas, prostate, skin, stomach, leukemia, liver, lung, and uterus. Phenotypic traits also include characteristics such as longevity, appearance (e.g., baldness, obesity), strength, speed, endurance, fertility, and susceptibility or receptivity to particular drugs or therapeutic treatments.

[0150] Such correlations can be exploited in several ways. In the case of a strong correlation between a polymorphic form and a disease for which treatment is available, detection of the polymorphic form set in a human or animal patient may justify immediate administration of treatment, or at least the institution of regular monitoring of the patient. Detection of a polymorphic form correlated with serious disease in a couple contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo in vitro fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic set and human disease, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the patient can be motivated to begin simple life-style changes (e.g., diet, exercise) that can be accomplished at little cost to the patient but confer potential benefits in reducing the risk of conditions to which the patient may have increased susceptibility by virtue of variant alleles. After determining polymorphic form(s) present in an individual at one or more polymorphic sites, this information can be used in a number of methods.

[0151] Determination of which polymorphic forms occupy a set of polymorphic sites in an individual identifies a set of polymorphic forms that distinguishes the individual. See generally National Research Council, The Evaluation of Forensic DNA Evidence (Eds. Pollard et al., National Academy Press, D.C., 1996). Since the polymorphic sites are within a 50,000 bp region in the human genome, the probability of recombination between these polymorphic sites is low. That low probability means the haplotype (the set of all 10 polymorphic sites) set forth in this application should be inherited without change for at least several generations. The more sites that are analyzed the lower the probability that the set of polymorphic forms in one individual is the same as that in an unrelated individual. Preferably, if multiple sites are analyzed, the sites are unlinked. Thus, polymorphisms of the invention are often used in conjunction with polymorphisms in distal genes. Preferred polymorphisms for use in forensics are diallelic because the population frequencies of two polymorphic forms can usually be determined with greater accuracy than those of multiple polymorphic forms at multi-allelic loci.

[0152] The capacity to identify a distinguishing or unique set of forensic markers in an individual is useful for forensic analysis. For example, one can determine whether a blood sample from a suspect matches a blood or other tissue sample from a crime scene by determining whether the set of polymorphic forms occupying selected polymorphic sites is the same in the suspect and the sample. If the set of polymorphic markers does not match between a suspect and a sample, it can be concluded (barring experimental error) that the suspect was not the source of the sample. If the set of markers does match, one can conclude that the DNA from the suspect is consistent with that found at the crime scene. If frequencies of the polymorphic forms at the loci tested have been determined (e.g., by analysis of a suitable population of individuals), one can perform a statistical analysis to determine the probability that a match of suspect and crime scene sample would occur by chance.

[0153] p(ID) is the probability that two random individuals have the same polymorphic or allelic form at a given polymorphic site. In diallelic loci, four genotypes are. possible: AA, AB, BA, and BB. If alleles A and B occur in a haploid genome of the organism with frequencies x and y, the probability of each genotype in a diploid organism are (see WO 95/12607):

Homozygote: p(AA)=x ²

Homozygote: p(BB)=y ²=(1−x)²

Single Heterozygote: p(AB)=p(BA)=xy=x(1−x)

Both Heterozygotes: p(AB+BA)=2xy=2x(1−x)

[0154] The probability of identity at one locus (i.e, the probability that two individuals, picked at random from a population will have identical polymorphic forms at a given locus) is given by the equation:

p(ID)=(x ²)²⁺(2xy)²⁺(y ²)².

[0155] These calculations can be extended for any number of polymorphic forms at a given locus. For example, the probability of identity p(ID) for a 3-allele system where the alleles have the frequencies in the population of x, y and z, respectively, is equal to the sum of the squares of the genotype frequencies:

p(ID)=x ⁴⁺(2xy)²⁺(2yz)²⁺(2xz)²⁺ z ⁴⁺ y ⁴

[0156] In a locus of n alleles, the appropriate binomial expansion is used to calculate p(ID) and p(exc).

[0157] The cumulative probability of identity (cum p(ID)) for each of multiple unlinked loci is determined by multiplying the probabilities provided by each locus:

cum p(ID)=p(ID1)p(ID2)p(ID3) . . . p(IDn)

[0158] The cumulative probability of non-identity for n loci (i.e. the probability that two random individuals will be different at 1 or more loci) is given by the equation:

cum p(nonID)=1−cum p(ID).

[0159] If several polymorphic loci are tested, the cumulative probability of non-identity for random individuals becomes very high (e.g., one billion to one). Such probabilities can be taken into account together with other evidence in determining the guilt or innocence of the suspect.

[0160] The object of paternity testing is usually to determine whether a male is the father of a child. In most cases, the mother of the child is known and thus, the mother's contribution to the child's genotype can be traced. Paternity testing investigates whether the part of the child's genotype not attributable to the mother is consistent with that of the putative father. Paternity testing can be performed by analyzing sets of polymorphisms in the putative father and the child.

[0161] If the set of polymorphisms in the child attributable to the father does not match the putative father, it can be concluded, barring experimental error, that the putative father is not the real father. If the set of polymorphisms in the child attributable to the father does match the set of polymorphisms of the putative father, a statistical calculation can be performed to determine the probability of coincidental match.

[0162] The probability of parentage exclusion (representing the probability that a random male will have a polymorphic form at a given polymorphic site that makes him incompatible as the father) is given by the equation (see WO 95/12607):

p(exc)=xy(1−xy)

[0163] where x and y are the population frequencies of alleles A and B of a diallelic polymorphic site. (At a triallelic site p(exc)=xy(1−xy)+yz(1−yz)+xz(1−xz)+3xyz(1−xyz))), where x, y and z and the respective population frequencies of alleles A, B and C). The probability of non-exclusion is:

p(non-exc)=1−p(exc)

[0164] The cumulative probability of non-exclusion (representing the value obtained when n loci are used) is thus:

cum p(non-exc)=p(non-exc1)p(non-exc2)p(non-exc3) . . . p(non-excn)

[0165] The cumulative probability of exclusion for n loci (representing the probability that a random male will be excluded) is:

cum p(exc)=1−cum p(non-exc).

[0166] If several polymorphic loci are included in the analysis, the cumulative probability of exclusion of a random male is very high. This probability can be taken into account in assessing the liability of a putative father whose polymorphic marker set matches the child's polymorphic marker set attributable to his/her father.

[0167] The polymorphisms of the invention may contribute to the phenotype of an organism in different ways. Some polymorphisms occur within a protein coding sequence and contribute to phenotype by affecting protein structure. The effect may be neutral, beneficial or detrimental, or both beneficial and detrimental, depending on the circumstances. For example, a heterozygous sickle cell mutation confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal. Other polymorphisms occur in noncoding regions but may exert phenotypic effects indirectly via influence on replication, transcription, and translation. A single polymorphism may affect more than one phenotypic trait. Likewise, a single phenotypic trait may be affected by polymorphisms in different genes. Further, some polymorphisms predispose an individual to a distinct mutation that is causally related to a certain phenotype.

[0168] Phenotypic traits include diseases that have known but hitherto unmapped genetic components. Phenotypic traits also include symptoms of, or susceptibility to, multifactorial diseases of which a component is or may be genetic, such as autoimmune diseases, inflammation, cancer, diseases of the nervous system, and infection by pathogenic microorganisms. Some examples of autoimmune diseases include rheumatoid arthritis, multiple sclerosis, diabetes (insulin-dependent and non-independent), systemic lupus erythematosus and Graves disease. Some examples of cancers include cancers of the bladder, brain, breast, colon, esophagus, kidney, leukemia, liver, lung, oral cavity, ovary, pancreas, prostate, skin, stomach and uterus. Phenotypic traits also include characteristics such as longevity, appearance (e.g., baldness, obesity), strength, speed, endurance, fertility, and susceptibility or receptivity to particular drugs or therapeutic treatments.

[0169] Correlation is performed for a population of individuals who have been tested for the presence or absence of a phenotypic trait of interest and for polymorphic markers sets. To perform such analysis, the presence or absence of a set of polymorphisms (i.e. a polymorphic set) is determined for a set of the individuals, some of whom exhibit a particular trait, and some of which exhibit lack of the trait. The alleles of each polymorphism of the set are then reviewed to determine whether the presence or absence of a particular allele is associated with the trait of interest. Correlation can be performed by standard statistical methods such as a -squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted. For example, it might be found that the presence of allele A1 at polymorphism A correlates with heart disease. As a further example, it might be found that the combined presence of allele A1 at polymorphism A and allele B1 at polymorphism B correlates with increased milk production of a farm animal.

[0170] Such correlations can be exploited in several ways. In the case of a strong correlation between a set of one or more polymorphic forms and a disease for which treatment is available, detection of the polymorphic form set in a human or animal patient may justify immediate administration of treatment, or at least the institution of regular monitoring of the patient. Detection of a polymorphic form correlated with serious disease in a couple contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo in vitro fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic set and human disease, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the patient can be motivated to begin simple life-style changes (e.g., diet, exercise) that can be accomplished at little cost to the patient but confer potential benefits in reducing the risk of conditions to which the patient may have increased susceptibility by virtue of variant alleles. Identification of a polymorphic set in a patient correlated with enhanced receptiveness to one of several treatment regimes for a disease indicates that this treatment regime should be followed.

[0171] For animals and plants, correlations between characteristics and phenotype are useful for breeding for desired characteristics. For example, Beitz et al., U.S. Pat. No. 5,292,639 discuss use of bovine mitochondrial polymorphisms in a breeding program to improve milk production in cows. To evaluate the effect of mtDNA D-loop sequence polymorphism on milk production, each cow was assigned a value of 1 if variant or 0 if wild type with respect to a prototypical mitochondrial DNA sequence at each of 17 locations considered.

[0172] The previous section concerns identifying correlations between phenotypic traits and polymorphisms that directly -or indirectly contribute to those traits. The present section describes identification of a physical linkage between a genetic locus associated with a trait of interest and polymorphic markers that are not associated with the trait, but are in physical proximity with the genetic locus responsible for the trait and co-segregate with it. Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander et al., Proc. Natl. Acad. Sci. (USA) 83, 7353-7357 (1986); Lander et al., Proc. Natl. Acad. Sci. (USA) 84, 2363-2367 (1987); Donis-Keller et al., Cell 51, 319-337 (1987); Lander et al., Genetics 121, 185-199 (1989)). Genes localized by linkage can be cloned by a process known as directional cloning. See Wainwright, Med. J. Australia 159, 170 -174 (1993); Collins, Nature Genetics 1, 3-6 (1992) (each of which is incorporated by reference in its entirety for all purposes).

[0173] Linkage studies are typically performed on members of a family. Available members of the family are characterized for the presence or absence of a phenotypic trait and for a set of polymorphic markers. The distribution of polymorphic markers in an informative meiosis is then analyzed to determine which polymorphic markers co-segregate with a phenotypic trait. See, e.g., Kerem et al., Science 245, 1073-1080 (1989); Monaco et al., Nature 316, 842 (1985); Yamoka et al., Neurology 40, 222-226 (1990); Rossiter et al., FASEB Journal 5, 21-27 (1991).

[0174] Linkage is analyzed by calculation of LOD (log of the odds) values. A lod value is the relative likelihood of obtaining observed segregation data for a marker and a genetic locus when the two are located at a recombination fraction, versus the situation in which the two are not linked, and thus segregating independently (Thompson & Thompson, Genetics in Medicine (5th ed, W.B. Saunders Company, Philadelphia, 1991); Strachan, “Mapping the human genome” in The Human Genome (BIOS Scientific Publishers Ltd, Oxford), Chapter 4). A series of likelihood ratios are calculated at various recombination fractions ( ), ranging from =0.0 (coincident loci) to =0.50 (unlinked). Thus, the likelihood at a given value of is: probability of data if loci linked at to probability of data if loci unlinked. The computed likelihood is usually expressed as the log₁₀ of this ratio (i.e., a lod score). For example, a lod score of 3 indicates 1000:1 odds against an apparent observed linkage being a coincidence. The use of logarithms allows data collected from different families to be combined by simple addition. Computer programs are available for the calculation of lod scores for differing values of (e.g., LIPED, MLINK (Lathrop, Proc. Nat. Acad. Sci. (USA) 81, 3443-3446 (1984)). For any particular lod score, a recombination fraction may be determined from mathematical tables. See Smith et al., Mathematical tables for research workers in human genetics (Churchill, London, 1961); Smith, Ann. Hum. Genet. 32, 127-150 (1968). The value of at which thelod score is the highest is considered to be the best estimate of the recombination fraction.

[0175] Positive lod score values suggest that the two loci are linked, whereas negative values suggest that linkage is less likely (at that value of) than the possibility that the two loci are unlinked. By convention, a combined lod score of +3 or greater (equivalent to greater than 1000:1 odds in favor of linkage) is considered definitive evidence that two loci are linked. Similarly, by convention, a negative lod score of −2 or less is taken as definitive evidence against linkage of the two loci being compared. Negative linkage data are useful in excluding a chromosome or a segment thereof from consideration. The search focuses on the remaining non-excluded chromosomal locations.

[0176] The invention further provides transgenic nonhuman animals capable of expressing an exogenous variant gene and/or having one or both alleles of an endogenous variant gene inactivated. Expression of an exogenous variant gene is usually achieved by operably linking the gene to a promoter and optionally an enhancer, and microinjecting the construct into a zygote. See Hogan et al., “Manipulating the Mouse Embryo, A Laboratory Manual,” Cold Spring Harbor Laboratory. (1989). Inactivation of endogenous variant genes can be achieved by forming a transgene in which a cloned variant gene is inactivated by insertion of a positive selection marker. See Capecchi, Science 244, 1288-1292 The transgene is then introduced into an embryonic stem cell, where it undergoes homologous recombination with an endogenous variant gene. Mice and other rodents are preferred animals. Such animals provide useful drug screening systems.

[0177] The invention further provides methods for assessing the pharmacogenomic susceptibility of a subject harboring a single nucleotide polymorphism to a particular pharmaceutical compound, or to a class of such compounds. Genetic polymorphism in drug-metabolizing enzymes, drug transporters, receptors for pharmaceutical agents, and other drug targets have been correlated with individual differences based on distinction in the efficacy and toxicity of the pharmaceutical agent administered to a subject. Pharmocogenomic characterization of a subjects susceptibility to a drug enhances the ability to tailor a dosing regimen to the particular genetic constitution of the subject, thereby enhancing and optimizing the therapeutic effectiveness of the therapy.

[0178] In cases in which a cSNP leads to a polymorphic protein that is ascribed to be the cause of a pathological condition, method of treating such a condition includes administering to a subject experiencing the pathology the wild type cognate of the polymorphic protein. Once administered in an effective dosing regimen, the wild type cognate provides complementation or remediation of the defect due to the polymorphic protein. The subject's condition is ameliorated by this protein therapy.

[0179] A subject suspected of suffering from a pathology ascribable to a polymorphic protein that arises from a cSNP is to be diagnosed using any of a variety of diagnostic methods capable of identifying the presence of the cSNP in the nucleic acid, or of the cognate polymorphic protein, in a suitable clinical sample taken from the subject. Once the presence of the cSNP has been ascertained, and the pathology is correctable by administering a normal or wild-type gene, the subject is treated with a pharmaceutical composition that includes a nucleic acid that harbors the correcting wild-type gene, or a fragment containing a correcting sequence of the wild-type gene. Non-limiting examples of ways in which such a nucleic acid may be administered include incorporating the wild-type gene in a viral vector, such as an adenovirus or adeno associated virus, and administration of a naked DNA in a pharmaceutical composition that promotes intracellular uptake of the administered nucleic acid. Once the nucleic acid that includes the gene coding for the wild-type allele of the polymorphism is incorporated within a cell of the subject, it will initiate de novo biosynthesis of the wild-type gene product. If the nucleic acid is further incorporated into the genome of the subject, the treatment will have long-term effects, providing de novo synthesis of the wild-type protein for a prolonged duration. The synthesis of the wild-type protein in the cells of the subject will contribute to a therapeutic enhancement of the clinical condition of the subject.

[0180] A subject suffering from a pathology ascribed to a SNP may be treated so as to correct the genetic defect. (See Kren et al., Proc. Natl. Acad. Sci. USA 96:10349-10354 (1999)). Such a subject is identified by any method that can detect the polymorphism in a sample drawn from the subject. Such a genetic defect may be permanently corrected by administering to such a subject a nucleic acid fragment incorporating a repair sequence that supplies the wild-type nucleotide at the position of the SNP. This site-specific repair sequence encompasses an RNA/DNA oligonucleotide which operates to promote endogenous repair of a subject's genomic DNA. Upon administration in an appropriate vehicle, such as a complex with polyethylenimine or encapsulated in anionic liposomes, a genetic defect leading to an inborn pathology may be overcome, as the chimeric oligonucleotides induces incorporation of the wild-type sequence into the subject's genome. Upon incorporation, the wild-type gene product is expressed, and the replacement is propagated, thereby engendering a permanent repair.

[0181] The invention further provides kits comprising at least one allele-specific oligonucleotide as described above. Often, the kits contain one or more pairs of allele-specific oligonucleotides hybridizing to different forms of a polymorphism. In some kits, the allele-specific oligonucleotides are provided immobilized to a substrate. For example, the same substrate can comprise allele-specific oligonucleotide probes for detecting at least 10, 100, 1000 or all of the polymorphisms shown in the Table. Optional additional components of the kit include, for example, restriction enzymes, reverse-transcriptase or polymerase, the substrate nucleoside triphosphates, means used to label (for example, an avidin-enzyme conjugate and enzyme substrate and chromogen if the label is biotin), and the appropriate buffers for reverse transcription, PCR, or hybridization reactions. Usually, the kit also contains instructions for carrying out the hybridizing methods.

[0182] Several aspects of the present invention rely on having available the polymorphic proteins encoded by the nucleic acids comprising a SNP of the inventions. There are various methods of isolating these nucleic acid sequences. For example, DNA is isolated from a genomic or cDNA library using labeled oligonucleotide probes having sequences complementary to the sequences disclosed herein.

[0183] Such probes can be used directly in hybridization assays. Alternatively probes can be designed for use in amplification techniques such as PCR.

[0184] To prepare a cDNA library, mRNA is isolated from tissue such as heart or pancreas, preferably a tissue wherein expression of the gene or gene family is likely to occur. cDNA is prepared from the mRNA and ligated into a recombinant vector. The vector is transfected into a recombinant host for propagation, screening and cloning. Methods for making and screening cDNA libraries are well known, See Gubler, U. and Hoffman, B. J. Gene 25:263-269 (1983) and Sambrook et al.

[0185] For a genomic library, for example, the DNA is extracted from tissue and either mechanically sheared or enzymatically digested to yield fragments of about 12-20 kb. The fragments are then separated by gradient centrifugation from undesired sizes and are constructed in bacteriophage lambda vectors. These vectors and phage are packaged in vitro, as described in Sambrook, et al. Recombinant phage are analyzed by plaque hybridization as described in Benton and Davis, Science 196:180-1 82 (1977). Colony hybridization is carried out as generally described in M. Grunstein et al. Proc. Natl. Acad. Sci. USA. 72:3961-3965 (1975). DNA of interest is identified in either cDNA or genomic libraries by its ability to hybridize with nucleic acid probes, for example on Southern blots, and these DNA regions are isolated by standard methods familiar to those of skill in the art. See Sambrook, et al.

[0186] In PCR techniques, oligonucleotide primers complementary to the two 3′ borders of the DNA region to be amplified are synthesized. The polymerase chain reaction is then carried out using the two primers. See PCR Protocols: a Guide to Methods and Applications (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), Academic Press, San Diego (1990). Primers can be selected to amplify the entire regions encoding a full-length sequence of interest or to amplify smaller DNA. segments as desired. PCR can be used in a variety of protocols to isolate cDNA's encoding a sequence of interest. In these protocols, appropriate primers and probes for amplifying DNA encoding a sequence of interest are generated from analysis of the DNA sequences listed herein. Once such regions are PCR-amplified, they can be sequenced and oligonucleotide probes can be prepared from the sequence.

[0187] Once DNA encoding a sequence comprising a cSNP is isolated and cloned, one can express the encoded polymorphic proteins in a variety of recombinantly engineered cells. It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of DNA encoding a sequence of interest. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes is made here.

[0188] In brief summary, the expression of natural or synthetic nucleic acids encoding a sequence of interest will typically be achieved by operably linking the DNA or cDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain, initiation sequences, transcription and translation terminators, and promoters useful for regulation of the expression of a polynucleotide sequence of interest. To obtain high level expression of a cloned gene, it is desirable to construct expression plasmids which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. The expression vectors may also comprise generic expression cassettes containing at least one independent terminator sequence, sequences permitting replication of the plasmid in both eukaryotes and prokaryotes. i.e., shuttle vectors, and selection markers for both prokaryotic and eukaryotic systems. See Sambrook et al.

[0189] A variety of prokaryotic expression systems may be used to express the polymorphic proteins of the invention. Examples include E. coli, Bacillus, Streptomyces, and the like.

[0190] It is preferred to construct expression plasmids which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. Examples of regulatory regions suitable for this purpose in E. coli are the promoter and operator region of the E. coli tryptophan biosynthetic pathway as described by Yanofsky, C., J. Bacterial. 158:1018-1024 (1984) and the leftward promoter of phage lambda (P) as described by Λ, I. and Hagen, D., Ann. Rev. Genet. 14:399-445 (1980). The inclusion of selection markers in DNA vectors transformed in E. coli is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol. See Sambrook et al. for details concerning selection markers for use in E. coli.

[0191] To enhance proper folding of the expressed recombinant protein, during purification from E. coli, the expressed protein may first be denatured and then renatured. This can be accomplished by solubilizing the bacterially produced proteins in a chaotropic agent such as guanidine HCl and reducing all the cysteine residues with a reducing agent such as beta-mercaptoethanol. The protein is then renatured, either by slow dialysis or by gel filtration. See U.S. Pat. No. 4,511,503. Detection of the expressed antigen is achieved by methods known in the art as radioimmunoassay, or Western blotting techniques or immunoprecipitation. Purification from E. coli can be achieved following procedures such as those described in U.S. Pat. No. 4,511,503.

[0192] Any of a variety of eukaryotic expression systems such as yeast, insect cell lines, bird, fish, and mammalian cells, may also be used to express a polymorphic protein of the invention. As explained briefly below, a nucleotide sequence harboring a cSNP may be expressed in these eukaryotic systems. Synthesis of heterologous proteins in yeast is well known. Methods in Yeast Genetics, Sherman, F., et al., Cold Spring Harbor Laboratory, (1982) is a well recognized work describing the various methods available to produce the protein in yeast. Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphogtycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired. For instance, suitable vectors are described in the literature (Botstein, et al., Gene 8:17-24 (1979); Broach, et al., Gene 8:121-133 (1979)).

[0193] Two procedures are used in transforming yeast cells. In one case, yeast cells are first converted into protoplasts using zymolyase, lyticase or glusulase, followed by addition of DNA and polyethylene glycol (PEG). The PEG-treated protoplasts are then regenerated in a 3% agar medium under selective conditions. Details of this procedure are given in the papers by J. D. Beggs, Nature (London) 275:104-109 (1978); and Hinnen, A., et al., Proc. Natl. Acad. Sci. USA, 75:1929-1933 (1978). The second procedure does not involve removal of the cell wall. Instead the cells are treated with lithium chloride or acetate and PEG and put on selective plates (Ito, H., et al., J. Bact, 153163-168 (1983)). cells and applying standard protein isolation techniques to the lysates:.

[0194] The purification process can be monitored by using Western blot techniques or radioimmunoassay or other standard techniques. The sequences encoding the proteins of the invention can also be ligated to various immunoassay expression vectors for use in transforming cell cultures of, for instance, mammalian, insect, bird or fish origin. Illustrative of cell cultures useful for the production of the polypeptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. A number of suitable host cell lines capable of expressing intact proteins have been developed in the art, and include the HEK293, BHK21, and CHO cell lines, and various human cells such as COS cell lines, HeLa cells, myeloma cell lines, Jurkat cells, etc. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMV promoter, a HSV tk promoter or pgk (phosphoglycerate kinase) promoter), an enhancer (Queen et al. Immunol. Rev. 89:49 (1986)) and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., an SV40 large T Ag poly A addition site), and transcriptional terminator sequences.

[0195] Other animal cells are available, for instance, from the American Type Culture Collection Catalogue of Cell Lines and Hybridomas (7th edition, (1992)). Appropriate vectors for expressing the proteins of the invention in insect cells are usually derived from baculovirus. Insect cell lines include mosquito larvae, silkworm, armyworm, moth and Drosophila cell lines such as a Schneider cell line (See Schneider J. Embryol. Exp. Morphol., 27:353-365 (1987). As indicated above, the vector, e.g., a plasmid, which is used to transform the host cell, preferably contains DNA sequences to initiate transcription and sequences to control the translation of the protein. These sequences are referred to as expression control sequences. As with yeast, when higher animal host cells are employed, polyadenylation or transcription terminator sequences from known mammalian genes need to be incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, J. et a/., J. Virol. 45: 773-781 (1983)). Additionally, gene sequences to control replication in the host cell may be Saveria-Campo, M., 1985, “Bovine Papilloma virus DNA a Eukaryotic Cloning Vector” in DNA Cloning Vol. II a Practical Approach Ed. D. M. Glover, IRL Press, Arlington, Va. pp. 213-238. The host cells are competent or rendered competent for transformation by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, electroporation and micro-injection of the DNA directly into the cells.

[0196] The transformed cells are cultured by means well known in the art (Biochemical Methods in Cell Culture and Virology, Kuchler, R. J., Dowden, Hutchinson and Ross, Inc., (1977)). The expressed polypeptides are isolated from cells grown as suspensions or as monolayers. The latter are recovered by well known mechanical, chemical or enzymatic means.

[0197] General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein “operably linked” refers to linkage of a promoter upstream from a DNA sequence such that the promoter mediates transcription of the DNA sequence. Specifically, “operably linked” means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the gene encoding the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression sequence. The term “vector”, refers to viral expression systems, autonomous self-replicating circular DNA (plasmids), and includes both expression and nonexpression plasmids.

[0198] The term “gene” as used herein is intended to refer to a nucleic acid sequence which encodes a polypeptide. This definition includes various sequence polymorphisms, mutations, and/or sequence variants wherein such alterations do not affect the function of the gene product. The term “gene” is intended to include not only coding sequences but also regulatory regions such as promoters, enhancers, termination regions and similar untranslated nucleotide sequences. The term further includes all introns and other DNA sequences spliced from the mRNA transcript, along with variants resulting from alternative splice sites.

[0199] A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A43 1 cells, human Co10205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells. Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein.

[0200] The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from. e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBac© kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). incorporated herein by reference. As used herein, an insect cell capable of expressing_a polynucleotide of the present invention is “transformed.” The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein.

[0201] The polymorphic protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein. The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art.

[0202] The polymorphic proteins produced by recombinant DNA technology may be purified by techniques commonly employed to isolate or purify recombinant proteins. Recombinantly produced proteins can be directly expressed or expressed as a fusion protein. The protein is then purified by a combination of cell lysis (e.g., sonication) and affinity chromatography. For fusion products, subsequent digestion of the fusion protein with an appropriate proteolytic enzyme releases the desired polypeptide. The polypeptides of this invention may be purified to substantial purity by standard techniques well known in the art, including selective precipitation with such substances as ammonium sulfate, column chromatography, immunopurification methods, and others. See, for instance, R. Scopes, Protein Purification: Principles and Practice, Springer-Verlag: New York (1982), incorporated herein by reference. For example, in an embodiment, antibodies may be raised to the proteins of the invention as described herein. Cell membranes are isolated from a cell line expressing the recombinant protein, the protein is extracted from the membranes and immunoprecipitated. The proteins may then be further purified by standard protein chemistry techniques as described above.

[0203] The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-Toyopearl@ or Cibacrom blue 3GA Sepharose B; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography. Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope (“Flag”) is commercially available from Kodak (New Haven, Conn.). Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an “isolated protein.”

[0204] The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen, such as polymorphic. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_(ab) and F_((ab′)2) fragments, and an F_(ab) expression library. In a specific embodiment, antibodies to human polymorphic proteins are disclosed.

[0205] The phrase “specifically binds to”, “immunospecifically binds to” or is “specifically immunoreactive with”, an antibody when referring to a protein or peptide, refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biological materials. Thus, for example, under designated immunoassay conditions, the specified antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. Of particular interest in the present invention is an antibody that binds immunospecifically to a polymorphic protein but not to its cognate wild type allelic protein, or vice versa. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) Antibodies, a Laboratory Manual. Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

[0206] Polyclonal and/or monoclonal antibodies that immunospecifically bind to polymorphic gene products but not to the corresponding prototypical or “wild-type” gene products are also provided. Antibodies can be made by injecting mice or other animals with the variant gene product or synthetic peptide. Monoclonal antibodies are screened as are described, for example, in Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988); Goding, Monoclonal antibodies, Principles and Practice (2d ed.) Academic Press, New York (1986). Monoclonal antibodies are tested for specific immunoreactivity with a variant gene product and lack of immunoreactivity to the corresponding prototypical gene product.

[0207] An isolated polymorphic protein, or a portion or fragment thereof, can be used as an immunogen to generate the antibody that bind the polymorphic protein using standard techniques for polyclonal and monoclonal antibody preparation. The full-length polymorphic protein can be used or, alternatively, the invention provides antigenic peptide fragments of polymorphic for use as immunogens. The antigenic peptide of a polymorphic protein of the invention comprises at least 8 amino acid residues of the amino acid sequence encompassing the polymorphic amino acid and encompasses an epitope of the polymorphic protein such that an antibody raised against the peptide forms a specific immune complex with the polymorphic protein. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of polymorphic that are located on the surface of the protein, e.g., hydrophilic regions.

[0208] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by injection with the polymorphic protein. An appropriate immunogenic preparation can contain, for example, recombinantly expressed polymorphic protein or a chemically synthesized polymorphic polypeptide. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.). human adjuvants such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. If desired, the antibody molecules directed against polymorphic proteins can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography, to obtain the IgG fraction.

[0209] The term “monoclonal antibody” or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that originates from the clone of a singly hybridoma cell, and that contains only one type of antigen binding site capable of immunoreacting with a particular epitope of a polymorphic protein. A monoclonal antibody composition thus typically displays a single binding affinity for a particular polymorphic protein with which it immunoreacts. For preparation of monoclonal antibodies directed towards a particular polymorphic protein, or derivatives, fragments, analogs or homologs thereof, any technique that provides for the production of antibody molecules by continuous cell line culture may be utilized. Such techniques include, but are not limited to, the hybridoma technique (see Kohler & Milstein, 1975 Nature 256: 495-497); the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

[0210] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to a polymorphic protein (see e.g., U.S. Pat. No. 4,946,778). In addition, methodologies can be adapted for the construction of F_(ab) expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F_(ab) fragments with the desired specificity for a polymorphic protein or derivatives, fragments, analogs or homologs thereof. Non-human antibodies can be “humanized” by techniques well known in the art. See e.g., U.S. Pat. No. 5,225,539. Antibody fragments that contain the idiotypes to a polymorphic protein may be produced by techniques known in the art including, but not limited to: (i) an F_((ab′)2) fragment produced by pepsin digestion of an antibody molecule; (ii) an F_(ab) fragment generated by reducing the disulfide bridges of an F_((ab′)2) fragment; (iii) an F_(ab) fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_(v) fragments.

[0211] Additionally, recombinant anti-polymorphic protein antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT International Application No. PCT/US86/02269; European Patent Application No. 184,187; European Patent Application No. 171,496; European Patent Application No. 173,494; PCT International Publication No. WO 86/01533; U.S. Pat. No. 4,816,567; European Patent Application No. 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) PNAS 84:3439-3443; Liu et al. (1987) J Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al. (1987) Cancer Res 47:999-1005; Wood et al. (1985) Nature 314:446-449; Shaw et al. (1988) J Natl Cancer Inst 80:1553-1559); Morrison (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214; U.S. Pat. No. 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J Immunol 141:4053-4060.

[0212] In one embodiment, methodologies for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art.

[0213] Anti-polymorphic protein antibodies may be used in methods known within the art relating to the detection, quantitation and/or cellular or tissue localization of a polymorphic protein (e.g., for use in measuring levels of the polymorphic protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for polymorphic proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody-derived CDR, are utilized as pharmacologically-active compounds in therapeutic applications intended to treat a pathology in a subject that arises from the presence of the cSNP allele in the subject.

[0214] An anti-polymorphic protein antibody (e.g., monoclonal antibody) can be used to isolate polymorphic proteins by a variety of immunochemical techniques, such as immunoaffinity chromatography or immunoprecipitation. An anti-polymorphic protein antibody can facilitate the purification of natural polymorphic protein from cells and of recombinantly produced polymorphic proteins expressed in host cells. Moreover, an anti-polymorphic protein antibody can be used to detect polymorphic protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polymorphic protein. Anti-polymorphic antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

1 880 1 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 1 cgctgacagg ggagtctgag ccacagaccc gctcacccga gtgcacgcac g 51 2 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 2 atggatagtc catctggttg gatgctgtgt actcgttggc ctcgttcagg t 51 3 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 3 aatacaaagc tgagtggaga gcagtgggtg aagaagtatg gcattccaag t 51 4 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 4 tattgttatt atgtattctg tttacgtgtt tctgtgtcac tgctaagaga a 51 5 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 5 caaggagcat tgaccgtgag aaatatgaac agtttgcgtt atatggctat g 51 6 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 6 tggcgtcgta ttttgggcat tcagtcgctg tcactgacgt caacggggat g 51 7 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 7 agggggccta tgaagcagag ctggcggtgc acctgcccca gggcgcccac t 51 8 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 8 gttactgtga agcgggcttc agctcggtgg tcactcaggc cggagagctg g 51 9 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 9 gtgacaagta cttcatagag gatggtcgcc tggtcatcca cagcctggac t 51 10 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 10 aaggagaaaa caatgaagaa ccgaatgaag acgaagactc tgaggctgag a 51 11 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 11 aaaacaatga agaaccgaac gaagatgaag actctgaggc tgagaatacc a 51 12 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 12 agaacggcca gcccctgtgg atcctggggg atgtcttcct caggtcctac t 51 13 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 13 ggactccagt gtccagggca tccagttaca tcctatcctg gcggccactc a 51 14 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 14 taagacgggc agctacaccc gcagcggtta cctgccagct gagcaactgg t 51 15 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 15 tccagcccaa ggccaatttt gatgcgcagc agtttgcagg gacctggctc c 51 16 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 16 aggtaggagg gcttggtctc caaacgccta ttgtttcatt ctccacagtg c 51 17 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 17 aacagccggc agatgtaact ggtaccgcct tgcccagggt gggccccgtg a 51 18 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 18 tccagcgccg ggcaggaggg gtcctagttg cctcccatct gcagagcttc c 51 19 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 19 atgtgcccac tgcattgggt tgtccgggag ttgatactgg tgggatcaca g 51 20 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 20 cagaatatgg aggcacagga gcttcttttt tatccactgt gctcgtgata g 51 21 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 21 gaataagaaa ttcaatctgg atgcattggt gacccatacc ctgccttttg a 51 22 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 22 gtgctccaga ggggccagca ggcacgggaa aaaccgaaac caccaaggac t 51 23 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 23 cagaggggcc agcaggcaca ggaaagaccg aaaccaccaa ggacttggct a 51 24 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 24 agcaatggga aagtttttta aaggattggc ttcttctggt gcttgggctt g 51 25 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 25 cttcttctgg tgcttgggct tgctttgatg aattcaaccg gattgagttg g 51 26 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 26 agcggcccac catggcccta gggtcatcaa caagtccagc agcaatcatg g 51 27 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 27 ccgatggcta tgagcaggct gctcgtgttg ctattgaaca cctggacaag a 51 28 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 28 caagttcctc aataaagtgg cagttttcag gttctactgg ctccacttct c 51 29 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 29 tcaccctcag gaggtggctg ttctgtgtcc acgacaacta cagaaacaac c 51 30 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 30 tcttcaacat cgtctattgg ctttattatg tgaactaaaa catggcctcc c 51 31 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 31 ggattttgga cagactccta gatggttatg acaatcgcct gagaccagga t 51 32 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 32 gggcccactt ccccctggac gtccagtgga acgacctgga ctacatggac t 51 33 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 33 tgaacgagcc ttccaacttc atcagaggct ctgaggacgg ctgccccaac a 51 34 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 34 aattccaaat gagctctcca accacatatt ttctgcgttt ttgatccaga c 51 35 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 35 aattccagat gagctctcca accacatatt ttctgcgttt ttgatccaga c 51 36 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 36 ggaccatctc tgtgaccaca cctgcagacg ctgtcattgg ccactactcg c 51 37 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 37 acccctggaa tagagaggat gctgtgttcc tgaagaatga ggctcagcgc a 51 38 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 38 tgacgtcatc catgtccaat gtccatacca tggccccccc aaaatgctct c 51 39 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 39 gaagggatat aactgaagca ataaattttt cacggttggc aaatgtggac a 51 40 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 40 aggactgttt ttcattcagc ttcagcgtga ttcccatggg ctcttctgtg a 51 41 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 41 atgtctcagg attctaccca aagcctgtgt gggtgatgtg gatgcggggt g 51 42 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 42 tggcaataat agtgccttcc ttgcttcttt tgctatgcct tgcattatgg t 51 43 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 43 ctgtgatatc tacatctggg cgcccttggc cgggacttgt ggggtccttc t 51 44 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 44 agggtctgcg acagggttac tttgtagaag ctcagcccaa gattgtcctg g 51 45 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 45 atggccagtg ctgggtcttt gctggagtga ccaccacagt gctgcgctgc c 51 46 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 46 gctctgtgga gtccatcaag aatgggctgg tctacatgaa gtacgacacg c 51 47 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 47 gcatccagtg ggtaggggac cctcgttgga aggatggctc cattgtcata c 51 48 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 48 tacacaacct agactacagt gacaacggca cgttcacttg tgacgtcaaa a 51 49 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 49 agtcccttct ccgtggcacc tacgcctatg gttttgagaa gccctctgcc a 51 50 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 50 agtcttactt tgccattaac cacaatcccg acgccaagga cttgaagcag c 51 51 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 51 actttgccat taaccacaac cccgatgcca aggacttgaa gcagctcgcg c 51 52 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 52 tggagcgagc gtggatccag ttcgctgcgg ggttgtttgg gtcaagttgc t 51 53 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 53 gttaccagac gctggagctg gagaaagagt ttcactacaa tcgctacctg a 51 54 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 54 tcaggtagcg attgtagtga aattccttct ccagctccag ggtctggtag c 51 55 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 55 gggaagcatt tgccaatcag tccagggcgg aaagggatgc cttcctgcag g 51 56 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 56 acagccagcg gtttggcctg caccatgtca acttcagcga cagcagcaag t 51 57 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 57 atctggtcac cctgcagaac ctgggtgtgt cccactaccg tttttccatc t 51 58 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 58 tggtgtgggc cttggtgaac tctagaacgc ggctaatgtc tcctggtttg g 51 59 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 59 ggaagctgac tccagaggcc atgcctgacc tcaactcctc cactgactct g 51 60 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 60 gtagtgagga acaagccaga gctgtccaga tgagtacaaa agtcctgatc c 51 61 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 61 agttggaagt gaatggatcg cagcattcac tgacctgtgc ttttgaggac c 51 62 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 62 taaatattcg agacattgac aagatttatg ttcgaacagg tatctaccat g 51 63 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 63 agatctttga ggaaggggaa tctgatgatg agtttgacat ggatgagaat c 51 64 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 64 ttctgacgca catgttttgt acatttcaga ccaaggaaaa cctctttttt g 51 65 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 65 ttagtatcat tcactgtgat ctaaagcctg aaaatatcct tctttgtaac c 51 66 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 66 aggtatatac catcatgtac agttgctggc atgagaaagc agatgagcgt c 51 67 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 67 tggctccggc tacaccaaca tcatgcgggt gctaagcata tcctgagacg c 51 68 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 68 gcttgccaat ttctcgtctg tatgccaagt actttcaagg agatctgaat c 51 69 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 69 ctgtggagta catgtagctg aagagtcgct caatcttcct caagggaaca c 51 70 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 70 acatcatatt ggcgctgctg acgggtgtac tgccccctgg catgctagat g 51 71 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 71 cagtgtagaa ataggggtgc tccatggcct ctcttgcagt aagccgtgac t 51 72 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 72 agctcaatgg tggctctgcg tgctcatccc gaagtgacct gcctggttcc g 51 73 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 73 aattcaaccc actcatctat ggcaacgatg tggattctgt ggatgttgca a 51 74 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 74 agaccccgcc gtcccctggc caagccgtgg agtgctgcca aggggactgg t 51 75 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 75 ctcacgcttt gcagtcatct ggtccaccta gcactccctc ctctcctcgg c 51 76 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 76 ttaacacgag ggagcctgtg atgctagcct gctatgtgtg gggcttctat c 51 77 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 77 cccctgtgat caatatcacc tggctgcgca acggccaaac tgtcactgag g 51 78 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 78 caccaccaga tgccatggag accctagtct gtgccctggg cctggccatc g 51 79 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 79 ccatggagac cctggtctgt gccctaggcc tggccatcgg cctggtgggc t 51 80 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 80 tggtctgtgc cctgggcctg gccattggcc tggtgggctt cctcgtgggc a 51 81 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 81 tgggcctggc catcggcctg gtggggttcc tcgtgggcac cgtcctcatc a 51 82 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 82 tcggcctggt gggcttcctc gtgggtaccg tcctcatcat catgggcaca t 51 83 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 83 gtttcctcat tagccctgtg acccctgcac acgcagggac ctacagatgt c 51 84 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 84 ttgacatcta ccatctatcc agggaagggg aagcccatga acttaggctc c 51 85 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 85 cttctagtag ttggccttca cccacagaac caagcttcaa aactggtatc g 51 86 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 86 ggtactcagt ggccatcatc ctctttacca tccttccctt ctttctcctt c 51 87 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 87 tggccatcat cctcttcacc atcctcccct tctttctcct tcatcgctgg t 51 88 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 88 aggagctcaa gcgtgaggcc gagactctac gggagcggga aggcgaggag t 51 89 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 89 tcatgggcaa cctaaggcac aagtgtgtgc gcaacttcac agcgctcaac g 51 90 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 90 cggaatacct ggccatcacc tctgagagca aagagaactg cacgggcgtc c 51 91 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 91 agagtggcga gtgggtcatc gtggatgccg tgggcaccta caacaccagg a 51 92 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 92 acaacaccag gaagtacgag tgctgtgccg agatctaccc ggacatcacc t 51 93 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 93 agaggctctt tctgcagaaa cttcccaaat tactttgcat gaaagatcat g 51 94 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 94 gtctaggatg gagatcctac aaacatgtca gtgggcagat gctgtatttt g 51 95 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 95 ataacttgca tgatcttgtc aaacagcttc atctgtactg cttgaataca t 51 96 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 96 ttacgtcgcc aaattcccag ggcacgttgc gcacgaactt cagtacggga t 51 97 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 97 tccctgtgac ccaggcaggt gcatgggtga cactggtcgt gacctggcca g 51 98 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 98 cggcacacag gccgctcgcc ggagctgtgg cccaccccca gcccctggcc a 51 99 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 99 agaactcgcg ggtctcccac tacattatca actcgctgcc caaccgccgt t 51 100 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 100 ctgcaactac cttgaaccag ttgagttgcg gatccaccct cagcagcagc c 51 101 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 101 cagcatgacc tggcactgta cttcgaggaa agttggggat ttcaccgtag t 51 102 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 102 ttgcaacttg aggtcggtgc ttagtatgag acagaagcca ttctgcagtg t 51 103 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 103 tttacagttt tcttactgca tcatctatgt cagaaatctg ttccttcagc t 51 104 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 104 agagccacta caaggtggac tactcgcgtt ttcacaagac ctacgaggtg g 51 105 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 105 tcacacctgt cctgaccctg gaggacgggt tctacgaagt tgactacaac a 51 106 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 106 gcaggatcac ctgcaccctc ttggggacca tgatgctcat ccagctgtct a 51 107 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 107 agtcagacac cagcttagaa atgactatgg gcaatgcctt gtttcttgat g 51 108 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 108 ggaggacagg caactcatca ccgaattagt catcagcaag atgaaccagc t 51 109 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 109 acccgttctt ctgcccaccc actgaagccc cagaccgtga cttcttggtg g 51 110 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 110 tctggaagcc ggacatcctc tgagcgagtc gactgatccg ctggcgaacc a 51 111 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 111 tcatcagaga ttcgatctcc tcgtcagtca cgtgctcccc ggaggccctg a 51 112 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 112 gctttgagga ggaggcgcgg ttgcgggacg acactgaggc ggccatccgc g 51 113 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 113 ttcggaaagg gcaagcagtg accctcatga tggatgccac caatatgcca g 51 114 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 114 acacccacag cagttttggt ttaggtttat ctgtaaatgg aaggttctgg c 51 115 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 115 tcttctccaa cagtctgcca cccgctgtcg ttggctgcgc ctccaaggcc c 51 116 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 116 ttgtggtcct ggcctcgcag ttcctatccc atgacccaga acagctcacc a 51 117 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 117 tcacagggaa aattcaacga gccaaacttc gagacaagga gtggaagatg t 51 118 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 118 tgactctccc cgacccgtcc caccatggtc tccacagcac tcccgacagc c 51 119 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 119 tccgcaaggc cttcctgaag atccttcact gctgactctg ctgcctgccc g 51 120 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 120 tcctcgtcgc cacactggtc atgccatggg ttgtctacct ggaggtggta g 51 121 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 121 ttgctctttg ctggttccct cttcatttaa gccgtatatt gaagaaaact g 51 122 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 122 tattgaagaa aactgtgtat aacgagatgg acaagaaccg atgtgaatta c 51 123 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 123 acgtgaacac cgacatctac tccaaagtgc tggtgaccgc cgtgtacctg g 51 124 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 124 attccttgat tgctaggacc ctttataaaa gcaccctgaa catacctact g 51 125 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 125 cttatgctgt gatcatttca gtgggtatcc ttggaaatgc tattctcatc a 51 126 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 126 tccgaaagaa gtcttgggag gtgtatcagg gagtgtgcca gaaagggggc t 51 127 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 127 agacacccct ttcccagctc gcctcaggga ggagggaccc aagggccccc t 51 128 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 128 gcccctcggc cttcgcggtg ctggtgaccg gactggcggc caccgacctg c 51 129 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 129 ccagactggt cctggtggtg gtggcggtct tcgtcgtctg ctggactccc a 51 130 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 130 cagcactcac catggaatcc ccgattcaga tcttccgcgg ggagccgggc c 51 131 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 131 cgatccagat cttccgcggg gagcctggcc ctacctgcgc cccgagcgcc t 51 132 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 132 tggatctgca cctcttcgac tactccgagc cagggaactt ctcggacatc a 51 133 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 133 cgctgcacct gtgcatcgcg ctgggttacg ccaatagcag cctcaacccc g 51 134 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 134 tggctgtgac ccgtccccgg gacggtgcag tggtgtgcat gctccagttc c 51 135 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 135 tggccttccc gatcaccatg ctgctgactg gtttcgtggg caacgcactg g 51 136 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 136 gggatgccac cttctgcttc atcgtgtcgc tggcggtggc tgatgtggcc g 51 137 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 137 ccatctcctt ctgtggctgt ctcacgcaga tgtatttcgt tttcatgttc g 51 138 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 138 ggtggaaagc cttctccacc tgtggctctc acctggctgt ggttctcctc t 51 139 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 139 acagcaccat cattgctgtg tatttcaacc ctctgtcctc ccactcagct g 51 140 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 140 actctccaat gtactttttc ctctctaacc tctccttctt ggacctctgc t 51 141 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 141 gacatcaggc gcacggtgcc aacctgcgcc atctgcaggc caagaagaag t 51 142 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 142 aggcgcacgg tgccaacctc cgccacctgc aggccaagaa gaagtttgtg a 51 143 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 143 cagccttctc catgcccagc tggcaactgg cactgtgggc accagcctac c 51 144 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 144 cctgtgctga tctggtcatg ggcctagcag tggtgccctt tggggccgcc c 51 145 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 145 cttgcccatt cagatgcact ggtacagggc cacccaccag gaagccatca a 51 146 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 146 ttggaagcgt gcatccagtg agacctatga ggcttgagtc ttttagtgcc t 51 147 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 147 gtgtgagcag agatgccaga accaaggtgg accgaacacc attacatatg g 51 148 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 148 tggcagctac cagcacactg cctccgccgt caataaaggc actgatggtc t 51 149 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 149 tggctcccat tgtctgggag ggcacgttca acatcgacat cctcaacgag c 51 150 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 150 acgtggacat ggagttccgc gaccatgtgg gcgtggagat cctgactccg c 51 151 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 151 acgtgggcgt ggagatcctg actccactgt tcggcaccct gcaccccggc t 51 152 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 152 ggccccagtc ccaggcctac atccctaagg acgagggcga tttctactac c 51 153 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 153 acgagagcca cctgaacaag tacctactgc gccacaaacc caccaaggtg c 51 154 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 154 ggggagatac tggctcaccc aggaacacag ggaacatcac cttatgccac a 51 155 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 155 acgcagtggc cgtgggctcc ctctgtgctc tttccgccag tcttctaggt t 51 156 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 156 ccatcgccac gctccctctg tcctcggcct gggccgtggt cttcttcatc a 51 157 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 157 gatggaacag ctcctcgggt gtcttatcac tttggctggc tcccccctgc c 51 158 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 158 gcggctgctg gtggatgggt gggcgggggg tgcagcctcc accccctccc c 51 159 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 159 cgcctgtaat ggctgtgaac atgcttaccc agcaggaggt ccctgtcgtt a 51 160 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 160 cattgactag gggctgtggg ggcatgcgcc caggtgtccc tccatcagag g 51 161 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 161 agcaggccaa gagagatctg tggaatgcat cttgttccag aataccagat a 51 162 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 162 cgctggcata ggacatggcg ggctttcccc ccgcagagct ctgggggcta c 51 163 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 163 aaataacaag gcattgaaga atggcagacg agcggaaaga cgaaggaaag g 51 164 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 164 aaggacgcaa cgctgccacc atggatagta gcacctggag ccccaagacc a 51 165 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 165 tgaaagtatt caatcccaga aggaagctgg aatttgccct tctgtttcta g 51 166 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 166 gctggcgcac tgctagcctc agaggagcca gcacctcctc agcccccgcg c 51 167 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 167 aaaaccagct acctgccttt ctggaggaac tttgccatga gaaagaaatt t 51 168 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 168 catgagtttt gatcccagct cttctttccc tggctttctg ggccatttct c 51 169 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 169 ttggagctgg aattactgtg tatgaggcct tagcagctgc tgatgagctt t 51 170 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 170 tcaacaccta cgtccacttc caaggtaaga tgaagggctt ctccctgctg g 51 171 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 171 tggcttgcac aaattgcttg aagactcgat ccatgtaagt ggactgtctt g 51 172 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 172 ctgggcagct gccctcacag tagttgccgt agtagccggt gggtgctatg a 51 173 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 173 gccgagcctg caccaccaca aagggtcggt gcgactcttc gcctgggtcc a 51 174 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 174 catagaaggc caggagtcag gagacttggg ttctgtcctg gattatacac c 51 175 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 175 ggagtcagga gacctgggtt ctgtcttgga ttatacacca gctcactgag g 51 176 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 176 ccatgcccac ccccgacgcc accaccccac aggccaaggg cttccgcagg g 51 177 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 177 atttaatgaa tttcctgaag actgtgagaa gtacaactga gaaatccctt t 51 178 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 178 aaaacaatga tatcgatgaa gttattattc ccacagctcc cttatacaaa c 51 179 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 179 caccatgaag cagttgctgc gggccttgga ggagggccgc gtgcgggaag t 51 180 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 180 tcctgtacaa agacaggaac ctccatattc ccaccatgga aaatgggcct g 51 181 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 181 ctgcggtgga gacgtcagag ctgccggggg agggggctcc tgcgccacag c 51 182 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 182 accagctgct cgtagtacac aggcaagcac ttctccttgc ctacctccat g 51 183 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 183 ctaccgccaa ctatgacttt gtcctgaaga agcggacctt caccaaggga g 51 184 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 184 tcccctggca gaactaccac ctgaatgact ggatggagga ggaataccgc c 51 185 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 185 acatccaggt ggtgttcgac gccgttaccg acatcatcat tgccaacaac c 51 186 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 186 cagtgacggc agggtcaaag tccttagcgt agccctcgtt aaggctgtag a 51 187 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 187 aaccagccca ctgtgagaag accaccgtgt tcaagtcttt gggaatggca g 51 188 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 188 ccacaatgtt aggagggtat ttttatatcc ctccagttaa caaatacagc a 51 189 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 189 ctgccatctt tcagccctct gaaactgtgt ccagcacaga atcttccctg g 51 190 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 190 gcgcttccca ggtccggaca attcgtcaga ctattgtcaa actggggaat a 51 191 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 191 ggcagctgaa gatcaccaat gctggcatgg tgtctgatga ggagttggag c 51 192 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 192 gcgaggtgtt tgtgtccaat atccttaagg acacgcaggt gactcgacag g 51 193 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 193 tgtacactgc cagaaaagga aaaggggcct tttgtaatgg tcaaaaacta c 51 194 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 194 tcttggtgac tgagttgggc tcttctagaa caccagagac tgtgagaatg g 51 195 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 195 tagagcgcac acaggcctcc agctgggcca tgtccgtctc atcatcccaa g 51 196 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 196 ctgacagcta caggctcttt cagtttcatt ttcactgggg cagtacaaat g 51 197 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 197 agaagttgaa ggggctggtg ccactgggac ccgaatcaag tcgacacact a 51 198 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 198 tgggttcagg gatgtagccc ttctccacag ccaggcggct cagggcaaac a 51 199 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 199 gccaatatag gatagggcac tacaggttcc ggtacagtga caccctggag c 51 200 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 200 acggggagga gctgcagatg gaacctgtgt gaggtgtctt ctgggacctg c 51 201 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 201 agaggttggg gggcgccgag cgcgaacggc cccgaaaggg gctgggctcc t 51 202 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 202 tagtgaaagg cctgaaatat atgctcgagg tggaaattgg cagaactacc t 51 203 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 203 ctccatcaac agcatccgga ctgcacggcg gctcgccgtg cggctggggc c 51 204 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 204 cgacgaggtg ctacgcgagg gcgagttgga gaagcgcagc gacagcctct t 51 205 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 205 ttttttccag cttacaatgg tacaggcagg agcctgggga aggtcctgtc c 51 206 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 206 agaagagagc ctgtgacact gccacttgtg tgactcatcg gctggcaggc t 51 207 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 207 tcatcctgag ttctaagaag ctcctcctca gtgactctgg cttctatctc t 51 208 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 208 ctctggttgt ccacgaggga gacaccgtaa ctctcaattg cagttatgaa g 51 209 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 209 aagtctgtgc tgatccacaa gccacgtggg tgagagacgt ggtcaggagc a 51 210 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 210 agggaggcgg ggagggtagc atgggcacac ggccctcaca gggactcact 50 211 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 211 agttgaaatc agagaggaat aaaaaagaca ttttatattt tattctgctc c 51 212 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 212 taagcatgag gtggcacgag gcaggcgttg gcgatgccac ctgggggtca c 51 213 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 213 ggtccccttg ctttatccca agctctgagg gacgcagcct ggcatggctc t 51 214 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 214 gtccccttgc tttatcccaa gctcgtaggg acgcagcctg gcatggctct g 51 215 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 215 ctttatccca agctcggagg gacgcgagcc tggcatggct ctggcctagc a 51 216 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 216 tagcagccag gtgacatggc caggctacct tcctgtacag gcactgtggg c 51 217 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 217 gccaggtgac atggccaggc acctttcctg tacaggcact gtgggctcct g 51 218 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 218 aggtgacatg gccaggcacc ttccttgtac aggcactgtg ggctcctggc c 51 219 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 219 aggtgacatg gccaggcacc ttccttgtac aggcactgtg ggctcctggc c 51 220 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 220 aggtgacatg gccaggcacc ttccttgtac aggcactgtg ggctcctggc c 51 221 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 221 aatccacaat cggcatcagg aagcccaagt cccagtggcc attagggtcc t 51 222 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 222 tccctatgag cctgcaaagg agacattcag gaatgagttc catgttcgag a 51 223 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 223 cagtgcatct gggaagattt ctacccgacc aacagttcct tcagcttcca t 51 224 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 224 caacagttcc ttcagcttcc atttcacccc tcatttatcc ctcaaccccc a 51 225 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 225 tgctctcctt tcccctgccc ccagaacttt tatccactta cctagattct a 51 226 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 226 tggccacagt gaaaaaggtc atgggaggag agaagcaaag taggaaggat c 51 227 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 227 accgcaccct ttccaccggt ggggggccca gtgaagttta acaaactgct g 51 228 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 228 cataccacgt tcactgcaag ggggggaacg tgtgggttgc tctattcaag a 51 229 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 229 gaaacccagt aggctcctgg aggccctggt cagcttgctt ggaatccagc a 51 230 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 230 tggtggtgct acccttggcc tcccagagtc ctgccaccct gctgccgcca c 51 231 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 231 agcccttctc cacccggata gattcttcac ccttggcccg cctttgcccc a 51 232 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 232 acccggatag attcctcacc cttggtccgc ctttgcccca ccctactctg c 51 233 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 233 gtgcctggac atttgccttg ctggatgggg actggggatg tgggagggag c 51 234 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 234 acgactttga gcctcgcgat cttttgagtc caacgtccag ctcgttctct g 51 235 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 235 tgcggcttaa aagggcaacc cgcgccggac ccttcctccc tagtcgcggg g 51 236 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 236 gagagaccat ttacttacat cagtttggtt tatagacatt tgaatcatat c 51 237 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 237 agtttcatta tacttttctc tccacgtttt gtctatgttg aaaattttct g 51 238 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 238 acaagacaga agctgaagtg catcccaaag gtgctcagag agccggcccg c 51 239 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 239 tcttccttct ccagccggca ggcccgcgcc gcttaggagg gagagcccac c 51 240 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 240 tggcgagtcc agggtcaccc acataaccat gcaccacggg tgctatgccg c 51 241 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 241 gagtccaggg tcacccacat accattgcac cacgggtgct atgccgcttc t 51 242 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 242 taccatgcac cacgggtgct atgccacttc ttacaggacc tttttagccc t 51 243 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 243 cctggaggca actgggtagg gtgcacaacg gcatgctttg gctggaacac g 51 244 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 244 cagaacggca tgctttggct ggaaccacgc atccctcctt ccacggccgg c 51 245 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 245 cagagctagc tctggctctt caggctacaa gttcacagtc cttcgctcct g 51 246 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 246 gtccttcgct cctgagcacc aggttcagtc tccaggaagg gatttggtga a 51 247 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 247 gatacctttg cgtggatcaa gcttgctgta cttgaccgtt tttatattac t 51 248 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 248 caaaaaaatt tataaactaa ttttggtacg tatgaatgat atctttgacc t 51 249 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 249 cctccttctc cccctttccc ctccccgccc ccaccttctt cctcctttcg g 51 250 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 250 ctgccctgcc acctgtctgt ctgtctccaa agaagttctg gtatgaactt g 51 251 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 251 ctgccctgcc acctgtctgt ctgtctccaa agaagttctg gtatgaactt g 51 252 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 252 tccctccagg actaggctgg aggaacccag tggggtcccc cctgagtggg c 51 253 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 253 cacatgtggg gacagggctg gtgtgcctgc tcccagcctc ttgctcagag c 51 254 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 254 ctaaagtcgg agtatcttct tccaaaattt cacgtcttgg cggccgttcc a 51 255 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 255 tttctagagg gggtctgttg aagatatgta actagtacac cccaaccccc a 51 256 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 256 ccccaacccc caacctcagt ggaaagcaat gcccagggat taggctatgg a 51 257 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 257 gcgcaggtca gagggcggcc gcagcgggcc tccgcgaggt ccccacgccg g 51 258 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 258 ctctatactg tacactcacc cataatcaaa caattacacc atggtataaa 50 259 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 259 tctatactgt acactcaccc ataatcaaac aattacacca tggtataaag 50 260 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 260 gccgaatagc ctgggtttgg aaaagtatgt ttttgaaata tgtgggatct c 51 261 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 261 tactgaccta aatcacaccc tagacttatc agagggaaat tctgaccata a 51 262 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 262 tgtccttgaa gaacatgcac ttggcgcgga tggcacaagc aaaatggtag a 51 263 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 263 cccgcgcccc agtaggagcc ccgcggccca gcaggtgcgg cgcgcacgga g 51 264 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 264 ccagcaggtg cggcgcgcac ggagcgcgcc ggccggcggc ttctcccgga g 51 265 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 265 tgaaacttga aaccgcctct ggagctgcca ttctgcagag tatttggaaa a 51 266 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 266 tccaagaaag ggtcatggaa gcttactggg aataatcctc tcaattagaa a 51 267 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 267 ggggggtttt tttttttttt ctctgttttt tttttttttt tttttttttt t 51 268 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 268 ctgggggttt tcggggagga accaaggctc acggagcctc ctgtgctgca 50 269 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 269 gggggttttc ggggaggaac caaggctcac ggagcctcct gtgctgcagt 50 270 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 270 gagttaattt atgtaagtca tattttatat ttttaagaag taccacttga a 51 271 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 271 cttacctcaa ataaatggct aactttatac atatttttaa agaaatattt a 51 272 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 272 cagcccccat tgtggtcaca ggaagcagag gaggccacgt tcttactagt t 51 273 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 273 cccaacctgg gtttggcaga catcagaatg atggagtaca ttttgcagat a 51 274 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 274 cacccccagg ttctcctagt tcagaaaaaa gctgtgaaag tggaagaagg a 51 275 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 275 tttattctat tcctatctgt ggatgggtaa atggctgggg ggccagccct g 51 276 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 276 agcctttgtg ctcccactca atacacaaag gcccctctct acatctggga a 51 277 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 277 aaaaaggccc ctctctacat ctggggatgc acctcttctt tgattccctg g 51 278 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 278 agcaacttgg ctgagcccca ctacatacag agaaatcatc aacctgactt a 51 279 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 279 taagagtttt caagatgtca aacttaaggc tgatcagcag atgggatgtg a 51 280 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 280 tttttaaaaa tccatccaca cacattggta aattaagtat aaattctttt g 51 281 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 281 aacgtcgatt cgcaccgtcc aacctgcccc gcccctccta cagctgtaac 50 282 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 282 acgtcgattc gcaccgtcca acctgccccg cccctcctac agctgtaact 50 283 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 283 cacttaatac cagagacccc ccccccttcc cctccccctt cccctccccc t 51 284 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 284 agacgtgtct gccacaggtc tcagggtaac agatgccctg tccactgaga g 51 285 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 285 tttgatggaa aggttgtcca cactgagaat tatcacacac ttgatcagga a 51 286 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 286 ccctccggat tcggcgcgcg tgcggmccgc cgcgagtgag ggttttcgtg g 51 287 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 287 tccaagctaa gcactgccac tgggggaaac tccaccttcc cactttccca c 51 288 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 288 ccacctccat cccagacagg tccctgccct tctctgtgca gtagcatcac c 51 289 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 289 cacctccatc ccagacaggt ccctcgcctt ctctgtgcag tagcatcacc t 51 290 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 290 gtctgataga agaggagcag gagaagcaaa tcgttaaaac ctagcgaatt c 51 291 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 291 tcaggagcaa ggcgaatgta tgacaccatg tccacaatgg tgtacataaa g 51 292 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 292 ttctgaagag gctgacgatt ttactgtctc atttttttcc tttctccaga a 51 293 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 293 ctagcttccc ttcccattca acacacacac acattcttgc tctacccaaa g 51 294 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 294 tgtctcaaac ccagcttgcc agctccaatg taccagcagc tggaatctga a 51 295 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 295 gtggctgggc tattccatcc atctggaagc acatttgagc ctccaggctt c 51 296 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 296 cgagcggcac ccagagcctg cacccgccct caccgtcctt ctgcgtcccc c 51 297 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 297 aggagccctc ttcggtgtcc ccgagcgcca cggtcaagac ccgcagcacc a 51 298 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 298 cggtcaagac ccgcagcacc aaagcgccgc ccccgcacct gcccctgtcg c 51 299 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 299 gagccgtgtg gctgtggcct ccgggcggcg gtggacggcg tgcgcttcat c 51 300 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 300 gggtgcacgg ccggccctgg gcaggcgtag ccatggagct gtggcgccaa t 51 301 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 301 atggggccgg tgtctcgcca ggaggcgcag acccggctcc agggccagcg c 51 302 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 302 agcatttgag gaagcataac tgacgtgtga agggggtgtg gggtacttgc c 51 303 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 303 agcatctgca gacgaccccc gcagcctttc cctcggaccc ccctcgaagc c 51 304 47 DNA Homo sapiens allele (22)...(0) single nucleotide polymorphism 304 cactgctgtg cagggcaggg atgctccagg cagacagccc agcaaag 47 305 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 305 cagcacagcg agcgctctca ttctgccttt tttcctcttc tcagccaact 50 306 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 306 tctgtagagc tctgaaaagg ttgacgatat agaggtcttg tatgttttta c 51 307 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 307 gacagacgag acagtgaggt atgtggggct gctccggaat ggtccggagg c 51 308 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 308 taactatgca agacaagact tggtcgtcac gttcgcgtct ctagttgatt t 51 309 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 309 aattaaaact ctaggtgtat acttacatgg aactagttta tttcctattt a 51 310 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 310 tgctcgcgcc gtgccactaa ggtcattccc gcctccgaga gcccagagcc g 51 311 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 311 cttttccctc ttaccctctc tctcttaaca tcgtaaacaa cagacttacg t 51 312 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 312 cctcttaccc tctctctctg aacattgtaa acaacagact tacgttaaac t 51 313 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 313 caaaatgtaa cagtggcttt tcaacgggag taaagcaaag tctctaaagc t 51 314 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 314 aaagatgttt gaatacttaa acactatcac aagatggcaa aatgctgaaa g 51 315 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 315 tggtggagcc actgcagtgt tatctcaaaa taagaatatt ttgttgagat a 51 316 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 316 cacttaactt gcatgtgcac agcttctggt aacaaatatc gctaaacctt a 51 317 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 317 atgtgattaa ttatgtgatg aaaacttttt ttataaatga tcttggtcta t 51 318 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 318 caatcagaat tgataagcac tgttcttcca ctccatttag caattatgtc a 51 319 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 319 tccatccctc ttttgggctc ttctgcaggg aagtaacatt tactgagcac c 51 320 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 320 tacccggaag ttgagctcaa tttcacttct gttttctggc cacaactgcc a 51 321 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 321 cccagtcctg cggctcctac tggggcgtgc gctggtcgga agattgctgg a 51 322 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 322 tactggggag tgcgctggtc ggaaggattg ctggactcgc tgaagagaga c 51 323 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 323 cggtccgtgg tccccggggg cgcaggtcgc agcgctcccg ccctccaggc g 51 324 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 324 ttctcaaaag gctgggggta tttatgtaag aacttattcc aaagtgactc t 51 325 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 325 aggaaagccg gagaattggg gcacgaagag ggggggcttt gatgacccgc 50 326 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 326 agattcatca gaataggatt tttgccaaat cccacccata tgctgttgag c 51 327 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 327 ccgctgtctc tgtcttcgct ttttattcaa gaagaataat gcgacgaaaa t 51 328 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 328 ccacttctct gggacacatt gccttttgtt ttctccagca tgcgcttgct c 51 329 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 329 catcatcatc atagtttact tcagctctta aatccccgag gagtctgccc t 51 330 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 330 ctcttgccca gccggctgca agttttgtaa gcgcgggaca gacactgctg a 51 331 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 331 aggttaccaa acaggaatac aacacttctc tcccttttct gctctagaag g 51 332 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 332 tgggtgatga tcactgtgct gcttgcggct catggcagag cattcagtgc c 51 333 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 333 acagactggc tgcagcatta ggaattaggt cattccgaaa ctcatcattg a 51 334 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 334 ggtcattccg aaactcatca ttgaaccagg aagaagaaga gttcaatctt a 51 335 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 335 agaatggcac tgaattcgtt tcttcgaaca cagatataat tgttggttca a 51 336 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 336 ctttcacttg gtgctggaga attcagaagt caagaacatg ctaagcataa g 51 337 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 337 ttcaaaagtc aagaacatgc taagcgtaag ggacccaagg tagaaagaga t 51 338 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 338 ttctccttcc agaatgaggc cctgggagga ccctcctagt gatctgttac t 51 339 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 339 actacataag gacagcaaca tgcctgtgga catgagagaa tttgtcttac t 51 340 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 340 gaaaaaaatc acaaggcaac tgtgagtccg ggaatctctt ctctgatcct t 51 341 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 341 tccgacccca cacaccctga gggaggccta ccctagcctc agccgctcct g 51 342 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 342 ataatccatg cctctgaata ttagagtggt ttcttggatg ggattttgaa t 51 343 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 343 gggattttga atatgcattt aagaacgttg ggaagaattt cacagatgat g 51 344 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 344 gaatatgcat ttaagaagtt gggaacaatt tcacagatga tgattggagg a 51 345 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 345 tcggcaaatc ttgaaagctg cagggtgcag agacatggat gtgacttccc a 51 346 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 346 aaggcataag aactaggagc tgctggacat ttcaatatga agggcaactc c 51 347 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 347 gaatgtgggg ataaggcatt gggactctat caggtatcct gaggagagac t 51 348 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 348 cagccgggag ctctgccagc tttggtgaag gagggtgctt gcctcgtgcc c 51 349 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 349 cgggagctct gccagctttg gcgaacgagg gtgcttgcct cgtgcccctt g 51 350 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 350 tgctcttgct gctgatggag gaggaggggg tggatcccgt ggagcctcca a 51 351 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 351 atgcttcccc caaccctagg gaatccacac ttaagataat tcgccacttc t 51 352 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 352 ccaaccctag ggaatcaaca cttaatataa ttcgccactt ctcctctttc t 51 353 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 353 agataattcg ccacttctcc tctttttctc tgctccgctc acggcttgca g 51 354 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 354 cgcagagccc cgccgtgggt ccgcccgctg aggcgccccc agccagtgcg c 51 355 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 355 cagcgccttc ttgctggcac ccaatggaag ccatgcgccg gaccacgacg t 51 356 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 356 tgcgccggac cacgacgtca cgcaggaaag ggacgaggtg tgggtggtgg g 51 357 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 357 gcaggtcttc tttgaaggcc tatggcaatg gctactccag caacggcaac a 51 358 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 358 attgtagtac aaatgactca ctgctataaa gcagtttttc tacttttaaa g 51 359 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 359 ataaacttag aataaaattg taaaaattgt atagagatat gcagaaggaa g 51 360 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 360 aggggtggaa ctgctgatgg gattttcctt cattcccttc tgataaaggt a 51 361 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 361 agcctcccca gagacaacac cgggaccctc atctctctcc tcaccctgct g 51 362 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 362 gtcttctccg cgcccacccc gctggtaagg ggaagtgggc gaagctggag c 51 363 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 363 ggggccgggc actgcccagg aaggggctcc gggagaggga gccggcggct g 51 364 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 364 agacgaagac cccaggaagt catcccgcaa tgggagagac acgaacaaac c 51 365 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 365 cccacgcctg ccaggagcaa gccgaagagc cagccggccg gcgcactccg a 51 366 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 366 aaacaaataa gcccttttta ctgacgatgc acccaacctt ttcagctgaa g 51 367 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 367 agagtcaaaa atccaagttt ggattgtaag cagccttgac agtaatcact g 51 368 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 368 aagcagcctt gacagtaatc actgagtggt agggaaaaaa agacagttgg g 51 369 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 369 aggcaaaagc tcacagtaaa tgtatcccag aacaggggcc taagtgaagg t 51 370 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 370 ctgctcccan cttcgccagc ctccagtgta caacttccgc gtgtagtggg c 51 371 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 371 ctgctcccaa cttcgccagc ctccagtgta caacttccgc gtgtagtggg c 51 372 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 372 cacttcactg aaagacacca tttatatacc caagggcaga aagtagaact t 51 373 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 373 gataggactc aagcttattt gggattctga tcaattcttt ctgatgttgt t 51 374 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 374 tacagccatc tgtacctact ggagctgcag aagggaagtc cactcagtca c 51 375 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 375 agcagtgcag ccccggcgcg gagcaaggag cctcggcccg cgcccggcgc c 51 376 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 376 gagaaaaagc atggtaccca accgattttc cacttttcag caatacttca c 51 377 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 377 taaagtttta agaaatgtca taatgtcatg agcttgaaat atctctaggc a 51 378 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 378 agcaaagaaa cactggcaga attcctgcat ttgcaaaatt ctaagttttg g 51 379 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 379 aaataaatgt tttcatagtc attacacttt acaatgggag tgctaaaatt c 51 380 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 380 aactgggttg ctctaagaac tgatgcctaa accgtctcag catggcctgt a 51 381 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 381 caatgcatga atctgtaccc ttcggagggc actcacatgc cgcccccagc 50 382 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 382 ttgttcatga tttcttgatg ttccttaatg gaaaactaag agatggaatt 50 383 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 383 gccgagtccg ctggtgggcg gaccctaggg gagcagccag tagggaagtt g 51 384 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 384 ccgagtccgc tggtgggcgg acccatgggg agcagccagt agggaagttg g 51 385 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 385 gggagcagcc agtagggaag ttgggggagt tccagaatca gggggcgtgg c 51 386 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 386 taatcgggag ggctggagca gaggggggcc ccgccgaggg gcgtggtcag t 51 387 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 387 gatgccaaaa aaacaaaggt gagaacccac aacacaggtc taaactcagc a 51 388 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 388 gtcttttaca gatggttttt caaaaagagt ccagtaaaat atttcacatt 50 389 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 389 cgttgttcct aatgtggatc taccatccct gtgttcatcg agattccggt c 51 390 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 390 tgggattaca ggtgcgcact accacgccaa gctaattttt gtatttttta g 51 391 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 391 ccttcagcac ccctgcagcg gaaaataatg agccgccgta gccgccatcc g 51 392 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 392 aaaaagctac agaaaagaaa tcactctgaa aaacacaatg actcagaggc a 51 393 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 393 cagggacatg cgggcacccc gtgggtcttt ggcggctcac aggacaatgg 50 394 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 394 gcaggcagag caccctggga ccccaggcag aaggacccct gccctccagt 50 395 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 395 taaacagctc agttcaggga ctggtgtaca agctggccac ccatctcagc c 51 396 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 396 ttacaggaca tcacctgcca tcttaaggtt taatatttac aaatgcctag t 51 397 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 397 ggccgatttt tccacaattt aaatctcagt tcacctggta tccagctcca g 51 398 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 398 gtttccacct ccccagacag gcatttcgag tgggaggcgg gagcacgtac c 51 399 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 399 tttccacctc cccagacagg cattctgagt gggaggcggg agcacgtacc g 51 400 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 400 ctaaacccaa atgggggctg ctggctgacc ccgagggtgc ctggccagtc c 51 401 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 401 ttttatcatt aaagtgccag aatggttctt taatgaaaac aaaaaacaaa g 51 402 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 402 ggagggttgg agtcactgac gaatgtgagc cgggccaggc ccatgcaaag g 51 403 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 403 gccacctgcc cgggctgtgg aggaggctcg cgctgaccag gcgctggggc 50 404 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 404 gcttctgccc acaccgcagg gacaagccct ggagaaatgg gagcntgggg a 51 405 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 405 catttctctt tgtacataat acatttacct ccctgcctcc tctcctttct a 51 406 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 406 caggggtcag cagagcttca gaggttgccc cacctgagcc cccacccggg a 51 407 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 407 cagaaagcag caaattagtg tttttaagga ccgaattcgg ctcccgcagc t 51 408 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 408 aagcagcaaa ttagtgtttt tcaggcccga attcggctcc cgcagctcct g 51 409 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 409 ctcccgcagc tcctgcatct ccatttgtct agattttatt tcttctttgc a 51 410 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 410 cccgcccagc ccgacgccta ctgagtcccc gcgctcgccc caccggcgcg c 51 411 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 411 ccagcccgac gcctactgag ccccgtgctc gccccaccgg cgcgctcttc g 51 412 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 412 agcccgacgc ctactgagcc ccgcgttcgc cccaccggcg cgctcttcgc g 51 413 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 413 cgacgcctac tgagccccgc gctcgtccca ccggcgcgct cttcgcgccc g 51 414 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 414 gctacgttta ctcacagcca gcgaaactga cattaaaata actaacaaac a 51 415 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 415 cgcctctgat ccaagccacc tcccgtcaga gaggtgtcat gggcttccaa a 51 416 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 416 ctctgcacaa gggaagccta tcctattttt ttttcctttg cgaaaacaga 50 417 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 417 aatgcctcag atcagtgacc caaggacctt ccagaatgga tgaaatagac 50 418 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 418 atgcctcaga tcagtgaccc aaggaccttc cagaatggat gaaatagacc 50 419 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 419 ccaagcggaa ggccattttc cctgctcttc ctcagttgtc cggggcgggg g 51 420 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 420 ctaattgtgt cgaatttcca ggattagagg aaaagttgct ccctttcagc c 51 421 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 421 aaagcaatca cagtgttaaa agaagacacg ttgaaatgat gcaggctgct c 51 422 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 422 ccagccagct catttcactt tacaccctca tggactgagt ttatactcac c 51 423 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 423 agccttcccg cagaaaaaga tgcagtcccc cagaccttct ctgtgctgat t 51 424 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 424 taccagaggc tgcatcggct gcgcggagag cagatggcgt cgtattttgg g 51 425 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 425 tggtgggcgc tccactgtat atggacagcc gggcagaccg aaaactggcc g 51 426 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 426 ctctcaacag gcaggcacca ccctggacct ggatctgggc ggaaagcaca g 51 427 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 427 ggttacaagt gtgaatgtag tcgtgcctat caaatggatc ttgctactgg c 51 428 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 428 gccgaggacg tgcgtggcaa cctgaagggc aacaccgagg ggctgcagaa g 51 429 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 429 tacgaggtgc ccttggagac cccgcgtgtc cacagccggg caccgtcccc a 51 430 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 430 gaggagccct tcggggtgat cgtgcgccgg cagctggacg gccgcgtgct g 51 431 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 431 gactgactgg ggaaaggaac ctaaactcga gtctgcctgg atgaatggag a 51 432 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 432 agttattcta gaggatacag aaatcgtcga agttcccgag aaactaggga g 51 433 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 433 ggaccagggg gccatgctgc tcaatatctc aggccacgtc aaggagagcg g 51 434 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 434 tgcttttcag ggcggaaaac tctctgttgt cctgcgagct gaagatatcc c 51 435 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 435 gtgtgggcct tggtgaactc tagcaagcgg ctaatgtctc ctggtttggt c 51 436 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 436 ggagatgtgg tcattcctag tgattttttt cagatagtgg gaggaagcaa c 51 437 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 437 aaggagaaga gaaagctgtt tatccgttcc atgggtgaag gtacaataaa t 51 438 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 438 gccactgtct cttccaaacc cttcaagcct tgtcttgctt gttctcgtct a 51 439 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 439 ttccaaatgc tgagcccaga gcgttatctc ctgcccatga gcaccacagt c 51 440 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 440 ctggaacagt ttcctcatta gccctctgac cccagcacac gcagggacct a 51 441 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 441 tcatcgctgg tgctccaaaa aaaaagatgc tgctgtaatg aaccaagagc c 51 442 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 442 ggatgctgtt gctctcccac agccattggg cgttccaaat gaaagccaag c 51 443 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 443 gccaatggca tccagaacaa ggaggtggag gtccgcatct ttcactgctg c 51 444 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 444 tctcgactaa cagcatttcc aaagacggag cgaatattgt ccacggttga g 51 445 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 445 gagtgccttg acgatacagc taattgagaa tcattttgtg gacgaatatg a 51 446 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 446 aagaagttat ggaattcctt ttattcaaac atcagcaaag acaagacagg g 51 447 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 447 gccgcctcag ccagcaagca ggcggttagg ccagtcctag ccaccacaga g 51 448 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 448 gggatgtact gcatggtgtt cttggcgctg tatgtgcagg cacgactctg t 51 449 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 449 tcaggtggtg ggaacctacc gttgcgttcc tggaaagaag ggaggctaca c 51 450 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 450 gtacagcggg cgggccacct cgggctctga gcaccaattt tgcggggggc g 51 451 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 451 ggatgctgga gagtggatca ctgtcgatca gacgacaaca gccaaccgtt a 51 452 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 452 gattcctcca gagctggtgt tggaacttcc catcaggcac cccaagtttg a 51 453 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 453 aagtttgagt ggttcaagga cctggcgctg aagtggtacg gcctccccgc c 51 454 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 454 aatttctata tcactgggga cagaggatat atggataaag atgggtattt c 51 455 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 455 tggaacaagt ggatatccga aaatgtctgc acacacccac agcagttttg g 51 456 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 456 aggagaggtg gtgaaggcat ttgtgatcct ggcctcgcag ttcctgtccc a 51 457 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 457 gtgatggacc ctctcatata tgccttccgc agccaagaga tgcggaagac c 51 458 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 458 ttccatctga ggtttataaa ccacgtattc aggcaaagtg gccagaatgg c 51 459 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 459 caagacctag ctccccagca gagagtggcc ccacaacaaa agaggtccag c 51 460 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 460 gacagagctg taccgtgaca ttttcgagca ccttcgggat gaatcaggca a 51 461 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 461 gagggcgatt tctactacct gggggcgttc ttcggggggt cggtgcaaga g 51 462 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 462 agtgtccctc accatggtca ccctggtcac cctgcctctg cttttccttc t 51 463 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 463 cctggaacgc gccttgtacc tgctcataag gagggtgctg cacttggggg t 51 464 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 464 gagcacgagg aagccatgaa tgcggtctac tcaggctacg tctacacgca c 51 465 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 465 agatactttc tataagcagt ttttacattg taggaagcag ctgaattcaa a 51 466 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 466 acactggaaa gcacaacagt tggcagttct gtctagaaaa taataattgc a 51 467 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 467 aacgctgccc tgactgagaa aggcatgatg ctcgctccac tgctggaacc g 51 468 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 468 catccaggac aacttctcgg tgactgaagt gcccttcact gagagcgcct g 51 469 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 469 cttcaaccct ggtcggagac aacggctcac catggccatc agaacagtgc g 51 470 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 470 ctgattcttc cgttcttctt gacttgtgcc accttgccag ccagctgctc g 51 471 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 471 acggccctgg agaaccagaa gaaggtgagg aagaagaaag tcttgattgc c 51 472 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 472 ggatggtgtc tgatgaggag ttggatcaga tgctggacag tgggcaaagc g 51 473 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 473 ttggggttgg cttggtttca ataagcaacg gggacactta caaattgctg c 51 474 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 474 gtgaccgagc ccgagtgccg cgaggtcttt caccgccgcg cccgcgccag c 51 475 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 475 cagtgcctcc cctgcggccc cggggtcaaa ggccgctgct tcgggcccag c 51 476 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 476 ggccaactct gctatggaca ccagactact ctgctgtgcg gtcatctgtc t 51 477 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 477 gcctggaaca ccaggctcct ctgccatgtc atgctttgtc tcctgggagc a 51 478 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 478 agccacccag accggagact cggccatcta cctctgtgct gtggaggcct a 51 479 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 479 cggccgtcta cctctgtgct gtggacgcct attctaacga ctacaagctc a 51 480 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 480 cagaacaaaa gcaaatggaa ttggatagca tcctggtggc cctgctgcag a 51 481 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 481 gaaacccgga agcactgtaa ttgcggggtc tataaatgca catggctctg t 51 482 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 482 tgtattcctg taatggggct gatgatatat atgatggtta tggaccacca c 51 483 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 483 gcccctgagc agtcaggacc cggcttccgt ccgtgagtgc cacgatccca g 51 484 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 484 ggagtgggtg ctgctgctct tgggagcttg tgctgcccct ccagcctggg c 51 485 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 485 cgtgtcctcc ctcccctatg cggtggcccc gctcagcctg ccccgagggg a 51 486 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 486 ggggtactat gggccccagt gtcagcttgt gattcagtgt gagcctttgg a 51 487 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 487 gctgggtacc atggactgta ctcactcttt gggaaacttc agcttcagct c 51 488 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 488 tgcagaaggc accacagaga ccggagggca gggcaagggc acctcgaaga c 51 489 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 489 gtgtgtgtgt aatggtgtgg ctgtatgctc caaccaagat cttattactg a 51 490 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 490 cggaagctgg tgtcctactg cccccgaagg ttgcaacaac tgttgcccct c 51 491 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 491 ccagggcctc caggtccaag aggcccctct ggagagcctg gtcttccagg g 51 492 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 492 gtgttttacg ctgaacgata ccaaatgccc acaggcataa aaggcccact a 51 493 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 493 tccaggaata ccaggtctgc ctggtgttcc tggaacaaga ggattaaaag g 51 494 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 494 agactgtgtt accaacagac catgcggaag tcaagtgcga tgtgaaggct t 51 495 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 495 ctccagttct acaacttgtg taaggcaagc acagtgtgga caggatttcc a 51 496 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 496 cagtttgggg gacagccatg cactgcgcct ctggtagcct ttcaaccatg c 51 497 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 497 ccaggctctc ccaggatctc atcaccgcgc ccccagggcc tcagcaaccc c 51 498 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 498 ccaagctccc atgacccaga caacgtcctt gaagacaagc tgggttaact g 51 499 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 499 tccacgtaga agcggaagcc gaggtgggag atgtacgcat tgatgggaag g 51 500 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 500 ttggtaggga cggaactcgg ggcgctggcg gtggcccgag tggagatagg a 51 501 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 501 gctggtttgc tcccaggagg ccaagcagtc agcctactgc ccctacagtc a 51 502 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 502 aagcatccga acaatcctca tctttggaag atgccaggag caattcggaa t 51 503 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 503 ccgcaccaac gccgacatca tcgaggccct gaggaagaag ggcttcaagg g 51 504 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 504 tccacgaccg ggtagagaac tacaaaccgc ggcagcgcaa gctccgcaac c 51 505 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 505 tcgttggaga tgacaagttc cggagtgagc tcggctgtct ggatgggaag g 51 506 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 506 agctggagca acagcaggaa cagcatcagg agcagcagca ggagcaggtg c 51 507 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 507 gtttggcata cctggatatt ttaattcagt ggagataaaa gacagcccac t 51 508 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 508 tattttaatc cagtggagat aaaagccagc ccactaggaa gtatatcaat a 51 509 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 509 aagtgaattc tatcttgcaa tgaacgagga aggaaaactc tatgcaaaga a 51 510 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 510 gatgagctct ccaaccacgt attttatgcg tttttgatcc agacccagat g 51 511 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 511 caccagcaag atgcccacga tcagccgaac ctgcccaagg cctgcttctt g 51 512 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 512 ttttccccag gggtcacaga ctgatgaccc acagaggtca gggtcttctg t 51 513 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 513 ggggtcacag actgataacc cacaggggtc agggtcttct gtccagtggt c 51 514 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 514 ctgatgaccc acagaagtca tggtcgttgc cccagtgatc tcagtcttct c 51 515 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 515 atatgtgtca tactgggagg tgttgtatgt gaggatgtac acccctgtgt t 51 516 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 516 aaggagcctc tctccttcca tgtcatctgg atcgcatcct tttacaacca t 51 517 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 517 attccagcac catcgttttc ctgtgcccct ggtccagggg aaacttcagc a 51 518 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 518 gtgctccctg atcctcgtga agcatgtggt agctcaagtt atgtggcatc t 51 519 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 519 aatgctgcga aagatatgaa tggaacgtct ttgcatggaa aagcaataaa a 51 520 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 520 aagtctgaga tctgcaagag gaagccgtgg aggaacaaga gggtggcttc c 51 521 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 521 gcggataagt agaggacctt catgtggtat ttgctggtga agttggttcg g 51 522 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 522 cttagacata caatatactt accttggagg tcacgtatgt ttgtccgcac a 51 523 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 523 ggagcgagcg tggatccagt tcgcgtcggg gttgtttggg tcaagttgct g 51 524 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 524 gccctgtgcc tgacggagag gcagagcaag atatggttcc agaaccgacg c 51 525 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 525 ctgggcacca tataggatag cccacgccgt catcaaagcc catgccagag t 51 526 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 526 gtggagggtg caggtgaagt agcatgcact tccttcttcc tctttcttga t 51 527 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 527 tgctccatca aaaatgaagc aaggctgcca tgtttaccga caccgggaaa a 51 528 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 528 caaaagcaag aaagttcttt gagaatttgc cagatggcac ttggaactta a 51 529 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 529 agtccaccgc cgcctcaggc cgtgctgctg gccgagtagg agaactgggg g 51 530 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 530 ggcactgaag aaatccctga catcacattg gcgctgctga cgggcgtact g 51 531 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 531 gggctgacaa ggtgctgatt ttcacggtgg acaaagcgtt cccatcgctt t 51 532 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 532 ttcaatgttg tatttgtcaa tatagccata taaatcttct gtccccagaa c 51 533 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 533 tgtaaaatcg aatatcatag tctgtgaacg tctggtacaa ttgcttgaag t 51 534 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 534 tcggctaggc agcctccatc ctcacccccc ttatcacatc cgcgtggcat g 51 535 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 535 ttcctcctct attcccggct cgggggccag ccagtgtacc tgcccactca g 51 536 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 536 tccgggataa gctccaggtg ctccatggta ggcgcctgga ggtgcctgtc c 51 537 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 537 aagcttgtca tgcctcacag cagtgagcac aagactgccc agcccaatgg a 51 538 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 538 acttacacct gtgtggtaga gcacactggg gctcctgagc ccatccttcg g 51 539 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 539 ggcctggtgg gcttcctcgt gggcatcgtc ctcatcatca tgggcacata t 51 540 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 540 ctgagcccag agcgttgtct cctgcgcatg agcaccacag tcaggccttg a 51 541 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 541 agcccggccg ggccccacgg ttcgcgcagg agagaacgtg accttgtcct g 51 542 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 542 ccggctgtgc tcaggggtgt ggggtgcgga tacagaggag cggctggtgg a 51 543 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 543 gaagatgccc tcctcagaca tgagttgaaa ggttatcaga aatgggtccg c 51 544 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 544 agatgccctc ctcagacatg agtggcaagg ttatcagaaa tgggtccgcc c 51 545 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 545 gcctcgggct tccactacgg tgtgctcgcc tgcgagggct gcaagggctt t 51 546 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 546 agcgggacgg tccggagcaa gcccacaggc agaggaggcg acagagggaa a 51 547 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 547 gtgccgggag tgagcgatga gctggtttct gttcctggcc cacagagtcg c 51 548 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 548 ggctataatc acaatgggga atggtttgaa gcccaaacca aaaatggcca a 51 549 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 549 atataaactt gtggtagttg gagcttgtgg cgtaggcaag agtgccttga c 51 550 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 550 tggatattct cgacacagca ggtcacgagg agtacagtgc aatgagggac c 51 551 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 551 ctgttcagga tctcctcatt ctgactgttc tcctgatgtc caaattggtt g 51 552 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 552 aggtcctcgc ggagctgggt ccggggcccg ggagggtagg tcagcgcaga c 51 553 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 553 ctggcgcact actcggacct gctcctcctg gcgggcctgg ggctgattga g 51 554 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 554 gcacaaggaa cggaattgct gtctggtttc tgctttaaca gcatttgatg c 51 555 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 555 cttcggggaa agttggggat ttcactgtag tcaaagatct gggcctgagt t 51 556 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 556 aggtcctcct cgaattggga tggccgaggt gcatcatcat catcccagag g 51 557 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 557 ctcagaccat gtccttcgga tgcacggtta cagagcacct ggggagcagg a 51 558 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 558 cgctttgaga cgcagctggg caccctggcg cagttcccca acacactcct g 51 559 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 559 gggggacgag gccatggagc gcttcggcga ggatgagggc ttcattaaag a 51 560 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 560 cattaaagaa gaggagaagc ccctggcccg caacgagttc cagcgccagg t 51 561 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 561 tggaggggat gctcattttg atgaacatga aaggtggacc aacaatttca g 51 562 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 562 gatgaaaggt ggaccaacaa tttcacagag tacaacttac atcgtgttgc g 51 563 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 563 attctacgat tccggtttgc tccagtgtaa actagcgctc ctttccgtaa c 51 564 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 564 cgctgccttc tcccgaaagg tctgctcctt cacgcgttcg gcttcccgca g 51 565 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 565 gtgaaggcat ttgtggtcct ggccttgcag ttcctgtccc atgacccaga a 51 566 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 566 gactgtcaca gggaaaattc aacgaaccaa gcttcgagac aaggagtgga a 51 567 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 567 gcaagaagtt gattatatga ctcaggctag gggtcagaga tcctctctgg c 51 568 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 568 aaggccaaca acctgctcta catcacccct gaggccttcc agaaccttcc c 51 569 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 569 gaatgtcttg agaatccagt gtctctgcag aaagcagtct tccaaacatg c 51 570 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 570 tctctctgga gaagatccaa cccatgacac aaaacggtca gcacccaacc t 51 571 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 571 agtgtctgga tgatctttgt ggtcattgca tccgttttca caaatgggct t 51 572 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 572 catcttctcc atcaacctct tcagcggcat tttcttcctc acgtgcatga g 51 573 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 573 tcttttgtgg acatctgctt ctcctccacc accgtcccca agatgctggc c 51 574 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 574 ggccctgaga gcaacaccac gggcaccaca gccttctcca tgcccagctg g 51 575 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 575 tggaagcgtg catccagtga gaccattgag gcttgagtct tttagtgcct g 51 576 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 576 gaggcgcggg gagccaggcc tgggccccgg gtccccaaga cccttgtgct c 51 577 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 577 actcgcacgt ggatcctgag gctgtgagag gtaaggaagg ctttgccaca g 51 578 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 578 cattgacagc gaggcctcct cagccttctt catggcgaag aagaagacgc c 51 579 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 579 tgacagagct gtaccgtgac attttgcagc accttcggga tgaatcaggc a 51 580 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 580 cactactatg tcttcaccga ccagctggcc gcggtgcccc gcgtgacgct g 51 581 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 581 tcggcagctg tcagtgctgg aggtgggcgc ctacaagcgc tggcaggacg t 51 582 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 582 ggtgtgcgtg gacgtggaca tggagatccg cgaccacgtg ggcgtggaga t 51 583 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 583 tccgctgttc ggcaccctgc accccagctt ctacggaagc agccgggagg c 51 584 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 584 caaggacgag ggcgatttct actacatggg ggggttcttc ggggggtcgg t 51 585 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 585 gttcttcggg gggtcggtgc aagagatgca gcggctcacc agggcctgcc a 51 586 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 586 cacatcgtgg tggagctgac ccaggatgac gctttgggct ccaggtggcg g 51 587 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 587 gtctgaaaga tttccacaag gacatgctga agccctcacc agggaagagc c 51 588 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 588 caagttcacc aacaactgct acaggcacgc gattgtcacc acctccatca a 51 589 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 589 tcctccggct tcgtcgtctt ctcctccctg gggtacatgg cacagaagca c 51 590 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 590 ctgcggtagc tgtcccaggc ctcgggccgc gccgcctcgt ccatgttgag g 51 591 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 591 gcataggaca tggcgggctt gccccgcgca gagctctggg ggctactgct a 51 592 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 592 caacccctag aagacctggc tggctggaaa gagctcttcc agacaccagt a 51 593 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 593 ccattgttca agacatccta cgtttggaaa tgcctgcaag caaaattgtc c 51 594 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 594 acaattcaga gagggagact gagcatacac cagcattgat catggtgcca a 51 595 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 595 atcaggaaag gtgttggatc actggtgcat catgaccagt gaggaagaag t 51 596 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 596 ccccaaacag gaagtccatg ggccctaccc tgacagcagc ttcttaactt c 51 597 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 597 cccaaacagg aagtccatgg gcccatccct gacagcagct tcttaacttc c 51 598 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 598 ctggaagaac tttgccatga gaaaggaatt ttggagaagt acggacattc a 51 599 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 599 aatgattaac aacaacctga gacacacgga tgaaatgttc tggaaccacg t 51 600 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 600 gcccccaggc atggctagct cgtgttccgt gcaggtgaag ctggagctgg g 51 601 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 601 cagctttcca tccattttta tttatagaca tactgctagt ggaaagacct a 51 602 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 602 caggtgtcct gcgagccacc cggggctccg ggtggcgggg gtggcggcgg c 51 603 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 603 agaggagaga gccgccctcg agcggggcaa ggcgattgag aaaaacctca a 51 604 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 604 gccagagttg cagcatcagg gccagcctga gcaggagacc cccagtccca t 51 605 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 605 taggaatgac agcagtagca gtaatgggaa ggccaaaaat ccccctggag a 51 606 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 606 tgttcctgga gcctcaatgg tacagcgtgc tcgagaagga cagtgtgact c 51 607 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 607 gggcacagaa acacagcagc gggagsagca acaccagcac tgccaacaga t 51 608 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 608 attgccattg tggtaactct gggtcgcatc atcttcagtg ccccaattgt g 51 609 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 609 gtgaagcggt gtatggggac agtgaacctc aaccaggcca ggggctcctt t 51 610 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 610 agtgacttca gtaaactctt gggtccactt tctgccaaaa agtaccttga g 51 611 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 611 cggtataacg tcaaaaatcc tgtttttcag ccaaggttca gaaattgcct c 51 612 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 612 aaggcgctat gtacagcctc ctgaagtgat tgggcctatg cggcccgagc a 51 613 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 613 tgaagatggt cctgatgggc aggaggtgga cccgccaaat ccagaggagg t 51 614 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 614 attactgaag ggtggagaac agaagcgtca tgaaaaaata tctgcttcat t 51 615 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 615 cacttcctct ttctctttgg atgcctcacc ctcctgttgg ggggcagatg g 51 616 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 616 gaagacaagg tggtacaaag ccctcaatct ctggttgtcc acgagggaga c 51 617 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 617 tgtaactctc aattgcagtt atgaaatgac taactttcga agcctactat g 51 618 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 618 gaagtgacta actttcgaag cctacaatgg tacaagcagg aaaagaaagc t 51 619 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 619 agcatattag ataagaaaga actttccagc atcctgaaca tcacagccac c 51 620 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 620 tacagaatat gtcgtcggtg ccccccactt ggagctggac cctgggagcg g 51 621 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 621 gtcggcttct tcaagcggaa ccggcacacc cctggaagaa gatgatgaag a 51 622 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 622 gtccatcact tcacttcagt tattccctag gaggttgtat agtcttctga 50 623 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 623 ctccagggat agttggacag aaggggagac cctggctacc caggaccagc t 51 624 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 624 gctatggagg caaaatggga ggaaggaaac gactacagaa atgatcagcg c 51 625 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 625 cggttactcc agttatggac aaagtctatt cacagtccta tggtggttat g 51 626 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 626 ggccgagcag ctgcggcgcc agctggaccc cctacgcaca gcgcatggag a 51 627 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 627 cagacttcca cagagtgctg gatgaacgcg gcctgccttg ccccagggtt a 51 628 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 628 tgaccacggg gtgctggatg cctgccttat acatcctgga ccggcggggg a 51 629 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 629 gcgccgcgag acaagggcag cggacgcgcc tgcggacttg agggacagtg a 51 630 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 630 ataagttaca atgctttttt tgtttaaaaa aaaaaaaagt ctgtacttta 50 631 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 631 ctgtggggct ggttctgtat ctgatcatca ttcgattacg aaataaaacg t 51 632 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 632 gtcagccgct acctcgactg gatcctatgg gcacatcaga gacaaggaag c 51 633 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 633 ccgggcagag ctgcgtctgc tgagggctca agttaaaagt ggagcagcac g 51 634 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 634 ccgggcagag ctgcgtctgc tgagggctca agttaaaagt ggagcagcac g 51 635 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 635 aatctccgca ctgcaggcca ggggcctggc cagctacaga gagaggtcac a 51 636 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 636 ccaggatcca ttttgaggat tatggtgtgc tgggacacca tcaactcctc a 51 637 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 637 caaatccccc cgtttcttca tcttggacat gctaaaatga aattacgcag t 51 638 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 638 ttcttcatct tgacatgcta aaatggaaat tacgcagttt ctctctatca a 51 639 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 639 ccgcctctgc tgctgctgct gctgcggcgt cccgcccagc cgcagcttcc c 51 640 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 640 atccaggctg agctggatca tctgaggcct ccagccaccc gttttccctt 50 641 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 641 ccaggctgag ctggatcatc tgaggcctcc agccacccgt tttcccttga 50 642 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 642 agcgagtcct ccgggaggcc cacaggttac tgcctccagc tgcagcagtg a 51 643 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 643 cgttccagag gagcatatct gctgactgat gacctgcaag agtcatccag a 51 644 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 644 ggaactcgag cacgtcgtcg ggggacccaa gatcaccggc gccctctggt 50 645 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 645 attcccgggg gagggggccc tgtaaggaaa ccagacaatc ccatgagact 50 646 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 646 tcccggggga gggggccctg taaggaaacc agacaatccc atgagactcc 50 647 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 647 gggcctgtct gcccagtgga ggaggttccg ctggtgttct agggggcatc 50 648 51 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 648 ctctcggcac tggtgactgg cgagagcctg gagcggcttc ggagagggct a 51 649 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 649 tcgtggccag gtccttctgc gtaagccctt gctctgccga ccttgctgga 50 650 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 650 ggtccaaatg caagtgctcc cggaaggacc caagatccgc tacagcgacg 50 651 50 DNA Homo sapiens allele (26)...(0) single nucleotide polymorphism 651 tccaaatgca agtgctcccg gaaggaccca agatccgcta cagcgacgtg 50 652 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 652 Pro Ala Glu Lys Asp Ala Val Pro Gln Thr Phe Ser Val Leu 1 5 10 653 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 653 Arg Leu His Arg Leu Arg Gly Glu Gln Met Ala Ser Tyr Phe 1 5 10 654 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 654 Gly Ala Pro Leu Tyr Met Asp Ser Arg Ala Asp Arg Lys Leu 1 5 10 655 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 655 Gln Ala Gly Thr Thr Leu Asp Leu Asp Leu Gly Gly Lys His 1 5 10 656 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 656 Lys Cys Glu Cys Ser Arg Ala Tyr Gln Met Asp Leu Ala Thr 1 5 10 657 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 657 Asp Val Arg Gly Asn Leu Lys Gly Asn Thr Glu Gly Leu Gln 1 5 10 658 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 658 Val Pro Leu Glu Thr Pro Arg Val His Ser Arg Ala Pro Ser 1 5 10 659 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 659 Pro Phe Gly Val Ile Val Arg Arg Gln Leu Asp Gly Arg Val 1 5 10 660 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 660 Trp Gly Lys Glu Pro Lys Leu Glu Ser Ala Trp Met Asn Gly 1 5 10 661 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 661 Ser Arg Gly Tyr Arg Asn Arg Arg Ser Ser Arg Glu Thr Arg 1 5 10 662 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 662 Gly Ala Met Leu Leu Asn Ile Ser Gly His Val Lys Glu Ser 1 5 10 663 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 663 Gln Gly Gly Lys Leu Ser Val Val Leu Arg Ala Glu Asp Ile 1 5 10 664 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 664 Pro Gly Asp Ile Ser Arg Leu Leu Glu Phe Thr Lys Ala His 1 5 10 665 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 665 Val Val Ile Pro Ser Asp Phe Phe Gln Ile Val Gly Gly Ser 1 5 10 666 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 666 Lys Arg Lys Leu Phe Ile Arg Ser Met Gly Glu Gly Thr Ile 1 5 10 667 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 667 Glu Gln Ala Arg Gln Gly Leu Lys Gly Leu Glu Glu Thr Val 1 5 10 668 1 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 668 Cys 1 669 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 669 Ser Phe Leu Ile Ser Pro Leu Thr Pro Ala His Ala Gly Thr 1 5 10 670 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 670 Trp Cys Ser Lys Lys Lys Asp Ala Ala Val Met Asn Gln Glu 1 5 10 671 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 671 Val Ala Leu Pro Gln Pro Leu Gly Val Pro Asn Glu Ser Gln 1 5 10 672 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 672 Gly Ile Gln Asn Lys Glu Val Glu Val Arg Ile Phe His Cys 1 5 10 673 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 673 Val Asp Asn Ile Arg Ser Val Phe Gly Asn Ala Val Ser Arg 1 5 10 674 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 674 Leu Thr Ile Gln Leu Ile Glu Asn His Phe Val Asp Glu Tyr 1 5 10 675 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 675 Tyr Gly Ile Pro Phe Ile Gln Thr Ser Ala Lys Thr Arg Gln 1 5 10 676 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 676 Ser Ala Ser Lys Gln Ala Val Arg Pro Val Leu Ala Thr Thr 1 5 10 677 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 677 Tyr Cys Met Val Phe Leu Ala Leu Tyr Val Gln Ala Arg Leu 1 5 10 678 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 678 Val Gly Thr Tyr Arg Cys Val Pro Gly Lys Lys Gly Gly Tyr 1 5 10 679 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 679 Gly Arg Ala Thr Ser Gly Ser Glu His Gln Phe Cys Gly Gly 1 5 10 680 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 680 Gly Glu Trp Ile Thr Val Asp Gln Thr Thr Thr Ala Asn Arg 1 5 10 681 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 681 Pro Glu Leu Val Leu Glu Leu Pro Ile Arg His Pro Lys Phe 1 5 10 682 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 682 Glu Trp Phe Lys Asp Leu Ala Leu Lys Trp Tyr Gly Leu Pro 1 5 10 683 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 683 Tyr Ile Thr Gly Asp Arg Gly Tyr Met Asp Lys Asp Gly Tyr 1 5 10 684 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 684 Ser Gly Tyr Pro Lys Met Ser Ala His Thr His Ser Ser Phe 1 5 10 685 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 685 Val Val Lys Ala Phe Val Ile Leu Ala Ser Gln Phe Leu Ser 1 5 10 686 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 686 Asp Pro Leu Ile Tyr Ala Phe Arg Ser Gln Glu Met Arg Lys 1 5 10 687 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 687 Leu Ala Thr Leu Pro Glu Tyr Val Val Tyr Lys Pro Gln Met 1 5 10 688 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 688 Leu Ala Pro Gln Gln Arg Val Ala Pro Gln Gln Lys Arg Ser 1 5 10 689 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 689 Leu Tyr Arg Asp Ile Phe Glu His Leu Arg Asp Glu Ser Gly 1 5 10 690 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 690 Asp Phe Tyr Tyr Leu Gly Ala Phe Phe Gly Gly Ser Val Gln 1 5 10 691 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 691 Leu Thr Met Val Thr Leu Val Thr Leu Pro Leu Leu Phe Leu 1 5 10 692 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 692 Arg Ala Leu Tyr Leu Leu Ile Arg Arg Val Leu His Leu Gly 1 5 10 693 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 693 Glu Glu Ala Met Asn Ala Val Tyr Ser Gly Tyr Val Tyr Thr 1 5 10 694 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 694 Ser Ala Ala Ser Tyr Asn Val Lys Thr Ala Tyr Arg Lys Tyr 1 5 10 695 8 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 695 Glu Ser Thr Thr Val Gly Ser Ser 1 5 696 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 696 Gln Gln Trp Ser Glu His His Ala Phe Leu Ser Gln Gly Ser 1 5 10 697 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 697 Asp Asn Phe Ser Val Thr Glu Val Pro Phe Thr Glu Ser Ala 1 5 10 698 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 698 Pro Gly Arg Arg Gln Arg Leu Thr Met Ala Ile Arg Thr Val 1 5 10 699 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 699 Leu Ala Gly Lys Val Ala Gln Val Lys Lys Asn Gly Arg Ile 1 5 10 700 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 700 Leu Glu Asn Gln Lys Lys Val Arg Lys Lys Lys Val Leu Ile 1 5 10 701 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 701 Val Ser Asp Glu Glu Leu Asp Gln Met Leu Asp Ser Gly Gln 1 5 10 702 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 702 Trp Leu Gly Phe Asn Lys Gln Arg Gly His Leu Gln Ile Ala 1 5 10 703 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 703 Glu Pro Glu Cys Arg Glu Val Phe His Arg Arg Ala Arg Ala 1 5 10 704 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 704 Leu Pro Cys Gly Pro Gly Val Lys Gly Arg Cys Phe Gly Pro 1 5 10 705 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 705 Ser Ala Met Asp Thr Arg Leu Leu Cys Cys Ala Val Ile Cys 1 5 10 706 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 706 Asn Thr Arg Leu Leu Cys His Val Met Leu Cys Leu Leu Gly 1 5 10 707 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 707 Gln Thr Gly Asp Ser Ala Ile Tyr Leu Cys Ala Val Glu Ala 1 5 10 708 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 708 Val Tyr Leu Cys Ala Val Asp Ala Tyr Ser Asn Asp Tyr Lys 1 5 10 709 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 709 Gln Lys Gln Met Glu Leu Asp Ser Ile Leu Val Ala Leu Leu 1 5 10 710 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 710 Gly Ser Thr Val Ile Ala Gly Ser Ile Asn Ala His Gly Ser 1 5 10 711 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 711 Pro Val Met Gly Leu Met Ile Tyr Met Met Val Met Asp His 1 5 10 712 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 712 Ser Ser Gln Asp Pro Ala Ser Val Arg Glu Cys His Asp Pro 1 5 10 713 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 713 Val Leu Leu Leu Leu Gly Ala Cys Ala Ala Pro Pro Ala Trp 1 5 10 714 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 714 Ser Leu Pro Tyr Ala Val Ala Pro Leu Ser Leu Pro Arg Gly 1 5 10 715 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 715 Tyr Gly Pro Gln Cys Gln Leu Val Ile Gln Cys Glu Pro Leu 1 5 10 716 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 716 Thr Met Asp Cys Thr His Ser Leu Gly Asn Phe Ser Phe Ser 1 5 10 717 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 717 Gly Thr Thr Glu Thr Gly Gly Gln Gly Lys Gly Thr Ser Lys 1 5 10 718 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 718 Cys Asn Gly Val Ala Val Cys Ser Asn Gln Asp Leu Ile Thr 1 5 10 719 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 719 Leu Val Ser Tyr Cys Pro Arg Arg Leu Gln Gln Leu Leu Pro 1 5 10 720 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 720 Arg Pro Gly Ser Pro Glu Gly Pro Leu Gly Pro Gly Gly Pro 1 5 10 721 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 721 Tyr Ala Glu Arg Tyr Gln Met Pro Thr Gly Ile Lys Gly Pro 1 5 10 722 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 722 Asn Pro Leu Val Pro Gly Thr Pro Gly Arg Pro Gly Ile Pro 1 5 10 723 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 723 Val Thr Asn Arg Pro Cys Gly Ser Gln Val Arg Cys Glu Gly 1 5 10 724 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 724 Ser Thr Thr Cys Val Arg Gln Ala Gln Cys Gly Gln Asp Phe 1 5 10 725 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 725 Gly Gly Gln Pro Cys Thr Ala Pro Leu Val Ala Phe Gln Pro 1 5 10 726 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 726 Ser Pro Arg Ile Ser Ser Pro Arg Pro Gln Gly Leu Ser Asn 1 5 10 727 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 727 Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 728 12 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 728 Ile Asn Ala Tyr Ile Ser His Leu Gly Phe Arg Phe 1 5 10 729 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 729 Leu His Ser Gly His Arg Gln Arg Pro Glu Phe Arg Pro Tyr 1 5 10 730 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 730 Cys Ser Gln Glu Ala Lys Gln Ser Ala Tyr Cys Pro Tyr Ser 1 5 10 731 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 731 Arg Thr Ile Leu Ile Phe Gly Arg Cys Gln Glu Gln Phe Gly 1 5 10 732 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 732 Asn Ala Asp Ile Ile Glu Ala Leu Arg Lys Lys Gly Phe Lys 1 5 10 733 9 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 733 Asp Arg Val Glu Asn Tyr Lys Pro Arg 1 5 734 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 734 Ile Gln Thr Ala Glu Leu Thr Pro Glu Leu Val Ile Ser Asn 1 5 10 735 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 735 Glu Gln Gln Gln Glu Gln His Gln Glu Gln Gln Gln Glu Gln 1 5 10 736 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 736 Leu Ser Phe Ile Ser Thr Glu Leu Lys Tyr Pro Gly Met Pro 1 5 10 737 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 737 Ile Leu Pro Ser Gly Leu Ala Phe Ile Ser Thr Gly Leu Lys 1 5 10 738 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 738 Phe Tyr Leu Ala Met Asn Glu Glu Gly Lys Leu Tyr Ala Lys 1 5 10 739 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 739 Gly Leu Asp Gln Lys Arg Ile Lys Tyr Val Val Gly Glu Leu 1 5 10 740 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 740 Ala Gly Leu Gly Gln Val Arg Leu Ile Val Gly Ile Leu Leu 1 5 10 741 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 741 Thr Leu Thr Ser Val Gly His Gln Ser Val Thr Pro Gly Glu 1 5 10 742 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 742 Gly Gln Lys Thr Leu Thr Pro Val Gly Tyr Gln Ser Val Thr 1 5 10 743 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 743 Thr Glu Ile Thr Gly Ala Thr Thr Met Thr Ser Val Gly His 1 5 10 744 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 744 Gly Val Tyr Ile Leu Thr Tyr Asn Thr Ser Gln Tyr Asp Thr 1 5 10 745 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 745 Pro Leu Ser Phe His Val Ile Trp Ile Ala Ser Phe Tyr Asn 1 5 10 746 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 746 Ser Thr Ile Val Phe Leu Cys Pro Trp Ser Arg Gly Asn Phe 1 5 10 747 13 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 747 Pro Asp Pro Arg Glu Ala Cys Gly Ser Ser Ser Tyr Val 1 5 10 748 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 748 Ala Lys Asp Met Asn Gly Thr Ser Leu His Gly Lys Ala Ile 1 5 10 749 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 749 Arg Ser Ala Arg Gly Ser Arg Gly Gly Thr Arg Gly Trp Leu 1 5 10 750 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 750 Asn Phe Thr Ser Lys Tyr His Met Lys Val Leu Tyr Leu Ser 1 5 10 751 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 751 Ile Gln Tyr Thr Tyr Leu Gly Gly His Val Cys Leu Ser Ala 1 5 10 752 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 752 Leu Asp Pro Asn Asn Pro Asp Ala Asn Trp Ile His Ala Arg 1 5 10 753 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 753 Cys Leu Thr Glu Arg Gln Ser Lys Ile Trp Phe Gln Asn Arg 1 5 10 754 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 754 Pro Tyr Arg Ile Ala His Ala Val Ile Lys Ala His Ala Arg 1 5 10 755 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 755 Lys Arg Lys Lys Glu Val His Ala Thr Ser Pro Ala Pro Ser 1 5 10 756 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 756 Ile Lys Asn Glu Ala Arg Leu Pro Cys Leu Pro Thr Pro Gly 1 5 10 757 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 757 Ala Arg Lys Phe Phe Glu Asn Leu Pro Asp Gly Thr Trp Asn 1 5 10 758 8 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 758 Phe Ser Tyr Ser Ala Ser Ser Thr 1 5 759 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 759 Pro Val Ser Ser Ala Asn Val Met Ser Gly Ile Ser Ser Val 1 5 10 760 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 760 Trp Glu Arg Phe Val His Arg Glu Asn Gln His Leu Val Ser 1 5 10 761 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 761 Gly Thr Glu Asp Leu Tyr Gly Tyr Ile Asp Lys Tyr Asn Ile 1 5 10 762 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 762 Lys Gln Leu Tyr Gln Thr Phe Thr Asp Tyr Asp Ile Arg Phe 1 5 10 763 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 763 Gly Ser Leu His Pro His Pro Pro Tyr His Ile Arg Val Ala 1 5 10 764 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 764 Leu Tyr Ser Arg Leu Gly Gly Gln Pro Val Tyr Leu Pro Thr 1 5 10 765 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 765 Ala Pro Pro Gly Ala Tyr His Gly Ala Pro Gly Ala Tyr Pro 1 5 10 766 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 766 Val Met Pro His Ser Ser Glu His Lys Thr Ala Gln Pro Asn 1 5 10 767 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 767 Thr Cys Val Val Glu His Thr Gly Ala Pro Glu Pro Ile Leu 1 5 10 768 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 768 Val Gly Phe Leu Val Gly Ile Val Leu Ile Ile Met Gly Thr 1 5 10 769 7 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 769 Gln Ser Val Val Ser Cys Ala 1 5 770 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 770 Pro Gly Pro Thr Val Arg Ala Gly Glu Asn Val Thr Leu Ser 1 5 10 771 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 771 Cys Ser Gly Val Trp Gly Ala Asp Thr Glu Glu Arg Leu Val 1 5 10 772 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 772 Ala Leu Leu Arg His Glu Leu Lys Gly Tyr Gln Lys Trp Val 1 5 10 773 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 773 Leu Leu Arg His Glu Trp Gln Gly Tyr Gln Lys Trp Val Arg 1 5 10 774 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 774 Gly Phe His Tyr Gly Val Leu Ala Cys Glu Gly Cys Lys Gly 1 5 10 775 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 775 Asp Gly Pro Glu Gln Ala His Arg Gln Arg Arg Arg Gln Arg 1 5 10 776 1 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 776 Glu 1 777 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 777 Asn His Asn Gly Glu Trp Phe Glu Ala Gln Thr Lys Asn Gly 1 5 10 778 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 778 Leu Val Val Val Gly Ala Cys Gly Val Gly Lys Ser Ala Leu 1 5 10 779 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 779 Ile Leu Asp Thr Ala Gly His Glu Glu Tyr Ser Ala Met Arg 1 5 10 780 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 780 Phe Gly His Gln Glu Asn Ser Gln Asn Glu Glu Ile Leu Asn 1 5 10 781 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 781 Leu Thr Tyr Pro Pro Gly Pro Arg Thr Gln Leu Arg Glu Asp 1 5 10 782 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 782 Gln Pro Gln Ala Arg Gln Glu Glu Gln Val Arg Val Val Arg 1 5 10 783 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 783 Asn Ala Val Lys Ala Glu Thr Arg Gln Gln Phe Arg Ser Leu 1 5 10 784 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 784 Ala Gln Ile Phe Asp Tyr Ser Glu Ile Pro Asn Phe Pro Arg 1 5 10 785 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 785 Asp Asp Asp Asp Ala Pro Arg Pro Ser Gln Phe Glu Glu Asp 1 5 10 786 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 786 His Val Leu Arg Met His Gly Tyr Arg Ala Pro Gly Glu Gln 1 5 10 787 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 787 Glu Thr Gln Leu Gly Thr Leu Ala Gln Phe Pro Asn Thr Leu 1 5 10 788 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 788 Glu Ala Met Glu Arg Phe Gly Glu Asp Glu Gly Phe Ile Lys 1 5 10 789 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 789 Glu Glu Glu Lys Pro Leu Ala Arg Asn Glu Phe Gln Arg Gln 1 5 10 790 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 790 Asp Ala His Phe Asp Glu His Glu Arg Trp Thr Asn Asn Phe 1 5 10 791 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 791 Arg Trp Thr Asn Asn Phe Thr Glu Tyr Asn Leu His Arg Val 1 5 10 792 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 792 Asp Ser Gly Leu Leu Gln Cys Lys Leu Ala Leu Leu Ser Val 1 5 10 793 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 793 Glu Ala Glu Arg Val Lys Glu Gln Thr Phe Arg Glu Lys Ala 1 5 10 794 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 794 Ala Phe Val Val Leu Ala Leu Gln Phe Leu Ser His Asp Pro 1 5 10 795 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 795 Thr Gly Lys Ile Gln Arg Thr Lys Leu Arg Asp Lys Glu Trp 1 5 10 796 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 796 Val Asp Tyr Met Thr Gln Ala Arg Gly Gln Arg Ser Ser Leu 1 5 10 797 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 797 Asn Asn Leu Leu Tyr Ile Thr Pro Glu Ala Phe Gln Asn Leu 1 5 10 798 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 798 Leu Arg Ile Gln Cys Leu Cys Arg Lys Gln Ser Ser Lys His 1 5 10 799 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 799 Leu Glu Lys Ile Gln Pro Met Thr Gln Asn Gly Gln His Pro 1 5 10 800 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 800 Trp Met Ile Phe Val Val Ile Ala Ser Val Phe Thr Asn Gly 1 5 10 801 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 801 Ser Ile Asn Leu Phe Ser Gly Ile Phe Phe Leu Thr Cys Met 1 5 10 802 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 802 Val Asp Ile Cys Phe Ser Ser Thr Thr Val Pro Lys Met Leu 1 5 10 803 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 803 Glu Ser Asn Thr Thr Gly Thr Thr Ala Phe Ser Met Pro Ser 1 5 10 804 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 804 Val His Pro Val Arg Pro Leu Arg Leu Glu Ser Phe Ser Ala 1 5 10 805 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 805 Arg Gly Ala Arg Pro Gly Pro Arg Val Pro Lys Thr Leu Val 1 5 10 806 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 806 Lys Ala Phe Leu Thr Ser His Ser Leu Arg Ile His Val Arg 1 5 10 807 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 807 Ser Glu Ala Ser Ser Ala Phe Phe Met Ala Lys Lys Lys Thr 1 5 10 808 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 808 Glu Leu Tyr Arg Asp Ile Leu Gln His Leu Arg Asp Glu Ser 1 5 10 809 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 809 Tyr Val Phe Thr Asp Gln Leu Ala Ala Val Pro Arg Val Thr 1 5 10 810 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 810 Leu Ser Val Leu Glu Val Gly Ala Tyr Lys Arg Trp Gln Asp 1 5 10 811 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 811 Val Asp Val Asp Met Glu Ile Arg Asp His Val Gly Val Glu 1 5 10 812 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 812 Phe Gly Thr Leu His Pro Ser Phe Tyr Gly Ser Ser Arg Glu 1 5 10 813 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 813 Glu Gly Asp Phe Tyr Tyr Met Gly Gly Phe Phe Gly Gly Ser 1 5 10 814 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 814 Gly Gly Ser Val Gln Glu Met Gln Arg Leu Thr Arg Ala Cys 1 5 10 815 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 815 Val Val Glu Leu Thr Gln Asp Asp Ala Leu Gly Ser Arg Trp 1 5 10 816 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 816 Lys Asp Phe His Lys Asp Met Leu Lys Pro Ser Pro Gly Lys 1 5 10 817 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 817 Thr Asn Asn Cys Tyr Arg His Ala Ile Val Thr Thr Ser Ile 1 5 10 818 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 818 Gly Phe Val Val Phe Ser Ser Leu Gly Tyr Met Ala Gln Lys 1 5 10 819 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 819 Met Asp Glu Ala Ala Arg Pro Glu Ala Trp Asp Ser Tyr Arg 1 5 10 820 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 820 Ser Pro Gln Ser Ser Ala Arg Gly Lys Pro Ala Met Ser Tyr 1 5 10 821 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 821 Leu Glu Asp Leu Ala Gly Trp Lys Glu Leu Phe Gln Thr Pro 1 5 10 822 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 822 Val Gln Asp Ile Leu Arg Leu Glu Met Pro Ala Ser Lys Ile 1 5 10 823 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 823 Ser Glu Arg Glu Thr Glu His Thr Pro Ala Leu Ile Met Val 1 5 10 824 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 824 Lys Val Leu Asp His Trp Cys Ile Met Thr Ser Glu Glu Glu 1 5 10 825 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 825 Gln Glu Val His Gly Pro Tyr Pro Asp Ser Ser Phe Leu Thr 1 5 10 826 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 826 Gln Glu Val His Gly Pro Ile Pro Asp Ser Ser Phe Leu Thr 1 5 10 827 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 827 Glu Leu Cys His Glu Lys Gly Ile Leu Glu Lys Tyr Gly His 1 5 10 828 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 828 Asn Asn Asn Leu Arg His Thr Asp Glu Met Phe Trp Asn His 1 5 10 829 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 829 Gly Met Ala Ser Ser Cys Ser Val Gln Val Lys Leu Glu Leu 1 5 10 830 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 830 Pro Ser Ile Phe Ile Tyr Arg His Thr Ala Ser Gly Lys Thr 1 5 10 831 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 831 Pro Pro Pro Pro Pro Gly Ala Pro Gly Gly Ser Gln Asp Thr 1 5 10 832 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 832 Arg Ala Ala Leu Glu Arg Gly Lys Ala Ile Glu Lys Asn Leu 1 5 10 833 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 833 Thr Gly Gly Leu Leu Leu Arg Leu Ala Leu Met Leu Gln Leu 1 5 10 834 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 834 Asp Ser Ser Ser Ser Asn Gly Lys Ala Lys Asn Pro Pro Gly 1 5 10 835 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 835 Leu Glu Pro Gln Trp Tyr Ser Val Leu Glu Lys Asp Ser Val 1 5 10 836 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 836 Gln Lys His Ser Ser Gly Xaa Ser Asn Thr Ser Thr Ala Asn 1 5 10 837 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 837 Trp Gly Thr Glu Asp Asp Ala Thr Gln Ser Tyr His Asn Gly 1 5 10 838 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 838 Arg Cys Met Gly Thr Val Asn Leu Asn Gln Ala Arg Gly Ser 1 5 10 839 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 839 Phe Ser Lys Leu Leu Gly Pro Leu Ser Ala Lys Lys Tyr Leu 1 5 10 840 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 840 Thr Ser Lys Ile Leu Phe Phe Ser Gln Gly Ser Glu Ile Ala 1 5 10 841 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 841 Tyr Val Gln Pro Pro Glu Val Ile Gly Pro Met Arg Pro Glu 1 5 10 842 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 842 Gly Pro Asp Gly Gln Glu Val Asp Pro Pro Asn Pro Glu Glu 1 5 10 843 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 843 Lys Gly Gly Glu Gln Lys Arg His Glu Lys Ile Ser Ala Ser 1 5 10 844 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 844 Ala Pro Gln Gln Glu Gly Glu Ala Ser Lys Glu Lys Glu Glu 1 5 10 845 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 845 Lys Val Val Gln Ser Pro Gln Ser Leu Val Val His Glu Gly 1 5 10 846 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 846 Leu Asn Cys Ser Tyr Glu Met Thr Asn Phe Arg Ser Leu Leu 1 5 10 847 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 847 Thr Asn Phe Arg Ser Leu Gln Trp Tyr Lys Gln Glu Lys Lys 1 5 10 848 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 848 Leu Asp Lys Lys Glu Leu Ser Ser Ile Leu Asn Ile Thr Ala 1 5 10 849 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 849 Glu Tyr Val Val Gly Ala Pro His Leu Glu Leu Asp Pro Gly 1 5 10 850 12 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 850 Phe Phe Lys Arg Asn Arg His Thr Pro Gly Arg Arg 1 5 10 851 7 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 851 Thr Ile Gln Pro Pro Arg Glu 1 5 852 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 852 Gly Ile Val Gly Gln Lys Gly Arg Pro Trp Leu Pro Arg Thr 1 5 10 853 12 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 853 Gly Gly Lys Met Gly Gly Arg Lys Arg Leu Gln Lys 1 5 10 854 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 854 Tyr Ser Ser Tyr Gly Gln Ser Leu Phe Thr Val Leu Trp Trp 1 5 10 855 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 855 Glu Gln Leu Arg Arg Gln Leu Asp Pro Leu Arg Thr Ala His 1 5 10 856 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 856 Ser Thr Glu Cys Trp Met Asn Ala Ala Cys Leu Ala Pro Gly 1 5 10 857 14 PRT Homo sapiens VARIANT (9)...(0) cSNP translation 857 His Gly Val Leu Asp Ala Cys Leu Ile His Pro Gly Pro Ala 1 5 10 858 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 858 Arg Asp Lys Gly Ser Gly Arg Ala Cys Gly Leu Glu Gly Gln 1 5 10 859 6 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 859 Thr Asp Phe Phe Phe Phe 1 5 860 13 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 860 Gly Ala Gly Ser Val Ser Asp His His Ser Ile Thr Lys 1 5 10 861 12 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 861 Arg Tyr Leu Asp Trp Ile Leu Trp Ala His Gln Arg 1 5 10 862 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 862 Ala Glu Leu Arg Leu Leu Arg Ala Gln Val Lys Ser Gly Ala 1 5 10 863 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 863 Ala Glu Leu Arg Leu Leu Arg Ala Gln Val Lys Ser Gly Ala 1 5 10 864 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 864 Pro His Cys Arg Pro Gly Ala Trp Pro Ala Thr Glu Arg Gly 1 5 10 865 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 865 Ile His Phe Glu Asp Tyr Gly Val Leu Gly His His Gln Leu 1 5 10 866 8 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 866 Asn Phe Ile Leu Ala Cys Pro Arg 1 5 867 13 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 867 Arg Glu Lys Leu Arg Asn Phe His Phe Ser Met Ser Arg 1 5 10 868 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 868 Leu Leu Leu Leu Leu Leu Arg Arg Pro Ala Gln Pro Gln Leu 1 5 10 869 8 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 869 Lys Arg Val Ala Gly Gly Leu Arg 1 5 870 9 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 870 Gly Lys Arg Val Ala Gly Gly Leu Arg 1 5 871 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 871 Ser Ser Gly Arg Pro Thr Gly Tyr Cys Leu Gln Leu Gln Gln 1 5 10 872 7 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 872 Gln Arg Ser Ile Ser Ala Asp 1 5 873 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 873 Arg Ala Pro Val Ile Leu Gly Pro Pro Thr Thr Cys Ser Ser 1 5 10 874 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 874 Met Gly Leu Ser Gly Phe Leu Thr Gly Pro Pro Pro Pro Gly 1 5 10 875 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 875 Leu Met Gly Leu Ser Gly Phe Leu Thr Gly Pro Pro Pro Pro 1 5 10 876 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 876 Pro Arg Thr Pro Ala Glu Pro Pro Pro Leu Gly Arg Gln Ala 1 5 10 877 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 877 Gly Thr Gly Asp Trp Arg Glu Pro Gly Ala Ala Ser Glu Arg 1 5 10 878 14 PRT Homo sapiens VARIANT (9)...(0) cSNP translation 878 Gln Gly Arg Gln Ser Lys Gly Leu Arg Arg Arg Thr Trp Pro 1 5 10 879 14 PRT Homo sapiens VARIANT (8)...(0) cSNP translation 879 Lys Cys Lys Cys Ser Arg Lys Asp Pro Arg Ser Ala Thr Ala 1 5 10 880 14 PRT Homo sapiens VARIANT (7)...(0) cSNP translation 880 Cys Lys Cys Ser Arg Lys Asp Pro Arg Ser Ala Thr Ala Thr 1 5 10 

What is claimed is:
 1. An isolated polynucleotide selected from the group consisting of: a) a nucleotide sequence comprising one or more polymorphic sequences (SEQ ID NOS:1-651); b) a fragment of said nucleotide sequence, provided that the fragment includes a polymorphic site in said polymorphic sequence; c) a complementary nucleotide sequence comprising a sequence complementary to one or more of said polymorphic sequences (SEQ ID NOS:1-651); and d) a fragment of said complementary nucleotide sequence, provided that the fragment includes a polymorphic site in said polymorphic sequence.
 2. The polynucleotide of claim 1, wherein said polynucleotide sequence is DNA.
 3. The polynucleotide of claim 1, wherein said polynucleotide sequence is RNA.
 4. The polynucleotide of claim 1, wherein said polynucleotide sequence is between about 10 and about 100 nucleotides in length.
 5. The polynucleotide of claim 1, wherein said polynucleotide sequence is between about 10 and about 90 nucleotides in length.
 6. The polynucleotide of claim 1, wherein said polynucleotide sequence is between about 10 and about 75 nucleotides in length.
 7. The polynucleotide of claim 1, wherein said polynucleotide is between about 10 and about 50 bases in length.
 8. The polynucleotide of claim 1, wherein said polynucleotide is between about 10 and about 40 bases in length.
 9. The polynucleotide of claim 1, wherein said polynucleotide is derived from a nucleic acid encoding a polypeptide related to angiopoietin, 4-hydroxybutyrate dehydrogenase, ATP-dependent RNA helicase, MHC Class I histocompatibility antigen, or phosphoglycerate kinase.
 10. The polynucleotide of claim 1, wherein said polymorphic site includes a nucleotide other than the nucleotide listed in Table 1, column 5 for said polymorphic sequence.
 11. The polynucleotide of claim 1, wherein the complement of said polymorphic site includes a nucleotide other than the complement of the nucleotide listed in Table 1, column 5 for the complement of said polymorphic sequence.
 12. The polynucleotide of claim 1, wherein said polymorphic site includes the nucleotide listed in Table 1, column 6 for said polymorphic sequence.
 13. The polynucleotide of claim 1, wherein the complement of said polymorphic site includes the complement of the nucleotide listed in Table 1, column 6 for said polymorphic sequence.
 14. An isolated allele-specific oligonucleotide that hybridizes to a first polynucleotide at a polymorphic site encompassed therein, wherein the first polynucleotide is chosen from the group consisting of: a) a nucleotide sequence comprising one or more polymorphic sequences (SEQ ID NOS:1-651) provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for said polymorphic sequence; b) a nucleotide sequence that is a fragment of said polymorphic sequence, provided that the fragment includes a polymorphic site in said polymorphic sequence; c) a complementary nucleotide sequence comprising a sequence complementary to one or more polymorphic sequences (SEQ ID NOS:1-651), provided that the complementary nucleotide sequence includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5; and d) a nucleotide sequence that is a fragment of said complementary sequence, provided that the fragment includes a polymorphic site in said polymorphic sequence.
 15. The oligonucleotide of claim 14, wherein the oligonucleotide does not hybridize under stringent conditions to a second polynucleotide selected from the group consisting of: a) a nucleotide sequence comprising one or more polymorphic sequences (SEQ ID NOS:1-651), wherein said polymorphic sequence includes the nucleotide listed in Table 1, column 5 for said polymorphic sequence; b) a nucleotide sequence that is a fragment of any of said nucleotide sequences; c) a complementary nucleotide sequence comprising a sequence complementary to one or more polymorphic sequences (SEQ ID NOS:1-651), wherein said polymorphic sequence includes the complement of the nucleotide listed in Table 1, column 5; and d) a nucleotide sequence that is a fragment of said complementary sequence, provided that the fragment includes a polymorphic site in said polymorphic sequence.
 16. The oligonucleotide of claim 15, wherein the oligonucleotide is between about 10 and about 51 bases in length.
 17. The oligonucleotide of claim 15, wherein the oligonucleotide identifies a polypeptide related to angiopoietin, 4-hydroxybutyrate dehydrogenase, ATP-dependent RNA helicase, MHC Class I histocompatibility antigen, or phosphoglycerate kinase.
 18. The oligonucleotide of claim 15, wherein the oligonucleotide is between about 15 and about 30 bases in length.
 19. A method of detecting a polymorphic site in a nucleic acid, the method comprising: a) contacting said nucleic acid with an oligonucleotide that hybridizes to a polymorphic sequence selected from the group consisting of SEQ ID NOS: 1-651, or its complement, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for said polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5; and b) determining whether said nucleic acid and said oligonucleotide hybridize; whereby hybridization of said oligonucleotide to said nucleic acid sequence indicates the presence of the polymorphic site in said nucleic acid.
 20. The method of claim 19, wherein said oligonucleotide does not hybridize to said polymorphic sequence when said polymorphic sequence includes the nucleotide recited in Table 1, column 5 for said polymorphic sequence, or when the complement of the polymorphic sequence includes the complement of the nucleotide recited in Table 1, column 5 for said polymorphic sequence.
 21. The method of claim 19, wherein said oligonucleotide identifies a polypeptide related to angiopoietin, 4-hydroxybutyrate dehydrogenase, ATP-dependent RNA helicase, MHC Class I histocompatibility antigen, or phosphoglycerate kinase.
 22. The method of claim 19, wherein said oligonucleotide is between about 15 and about 30 bases in length.
 23. A method of detecting the presence of a sequence polymorphism in a subject, the method comprising: a) providing a nucleic acid from said subject; b) contacting said nucleic acid with an oligonucleotide that hybridizes to a polymorphic sequence selected from the group consisting of SEQ ID NOS:1-651, or its complement, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in for said polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5; and c) determining whether said nucleic acid and said oligonucleotide hybridize; whereby hybridization of said oligonucleotide to said nucleic acid sequence indicates the presence of the polymorphism in said subject.
 24. A method of determining the relatedness of a first and second nucleic acid, the method comprising: a) providing a first nucleic acid and a second nucleic acid; b) contacting said first nucleic acid and said second nucleic acid with an oligonucleotide that hybridizes to a polymorphic sequence selected from the group consisting of SEQ ID NOS:1-651, or its complement, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for said polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column 5; c) determining whether said first nucleic acid and said second nucleic acid hybridize to said oligonucleotide; and d) comparing hybridization of said first and second nucleic acids to said oligonucleotide, wherein hybridization of the first and second nucleic acids to said oligonucleotide indicates the first and second nucleic acids are related.
 25. The method of claim 24, wherein said oligonucleotide does not hybridize to said polymorphic sequence when said polymorphic sequence includes the nucleotide recited in Table 1, column 5 for said polymorphic sequence, or when the complement of the polymorphic sequence includes the complement of the nucleotide recited in Table 1, column 5 for said polymorphic sequence.
 26. The method of claim 24, wherein the oligonucleotide is between about 10 and about 51 bases in length.
 27. The method of claim 24, wherein the oligonucleotide is between about 10 and about 40 bases in length.
 28. The method of claim 24, wherein the oligonucleotide is between about 15 and about 30 bases in length.
 29. An isolated polypeptide comprising a polymorphic site at one or more amino acid residues, wherein the protein is encoded by a polynucleotide selected from the group consisting of: polymorphic sequences SEQ ID NOS:1-651, or their complement, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for said polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column
 5. 30. The polypeptide of claim 29, wherein said polypeptide is translated in the same open reading frame as is a wild type protein whose amino acid sequence is identical to the amino acid sequence of the polymorphic protein except at the site of the polymorphism.
 31. The polypeptide of claim 29, wherein the polypeptide encoded by said polymorphic sequence, or its complement, includes the nucleotide listed in Table 2, column 6 or Table 3, column 5 for said polymorphic sequence, or the complement includes the complement of the nucleotide listed in Table 1, column
 6. 32. An antibody that binds specifically to a polypeptide encoded by a polynucleotide comprising a nucleotide sequence encoded by a polynucleotide selected from the group consisting of polymorphic sequences SEQ ID NOS:1-651, or its complement, provided that the polymorphic sequence includes a nucleotide other than the nucleotide recited in Table 1, column 5 for said polymorphic sequence, or the complement includes a nucleotide other than the complement of the nucleotide recited in Table 1, column
 5. 33. The antibody of claim 32, wherein said antibody binds specifically to a polypeptide encoded by a polymorphic sequence which includes the nucleotide listed in Table 1, column 6 for said polymorphic sequence.
 34. The antibody of claim 32, wherein said antibody does not bind specifically to a polypeptide encoded by a polymorphic sequence which includes the nucleotide listed in Table 1, column 5 for said polymorphic sequence.
 35. A method of detecting the presence of a polypeptide having one or more amino acid residue polymorphisms in a subject, the method comprising a) providing a protein sample from said subject; b) contacting said sample with the antibody of claim 34 under conditions that allow for the formation of antibody-antigen complexes; and c) detecting said antibody-antigen complexes, whereby the presence of said complexes indicates the presence of said polypeptide.
 36. A method of treating a subject suffering from, at risk for, or suspected of, suffering from a pathology ascribed to the presence of a sequence polymorphism in a subject, the method comprising: a) providing a subject suffering from a pathology associated with aberrant expression of a first nucleic acid comprising a polymorphic sequence selected from the group consisting of SEQ ID NOS:1-651, or its complement; and b) administering to the subject an effective therapeutic dose of a second nucleic acid comprising the polymorphic sequence, provided that the second nucleic acid comprises the nucleotide present in a wild type allele of the sequence polymorphism, thereby treating said subject.
 37. The method of claim 36, wherein the second nucleic acid sequence comprises a polymorphic sequence which includes the nucleotide listed in Table 1, column 5 for said polymorphic sequence.
 38. A method of treating a subject suffering from, at risk for, or suspected of suffering from a pathology ascribed to the presence of a sequence polymorphism in a subject, the method comprising: a) providing a subject suffering from a pathology associated with aberrant expression of a polymorphic sequence selected from the group consisting of polymorphic sequences SEQ ID NOS:1-651, or its complement; and b) administering to the subject an effective therapeutic dose of a polypeptide, wherein said polypeptide is encoded by a polynucleotide comprising a polymorphic sequence selected from the group consisting of SEQ ID NOS:1-651, or by a polynucleotide comprising a nucleotide sequence that is complementary to any one of polymorphic sequences SEQ ID NOS:1-651, provided that said polymorphic sequence includes the nucleotide listed in Table 1, column 6 for said polymorphic sequence, thereby treating said subject.
 39. A method of treating a subject suffering from, at risk for, or suspected of suffering from, a pathology ascribed to the presence of a sequence polymorphism in a subject, the method comprising: a) providing a subject suffering from, at risk for, or suspected of suffering from, a pathology associated with aberrant expression of a first nucleic acid comprising a polymorphic sequence selected from the group consisting of SEQ ID NOS:1-651, or its complement; and b) administering to the subject an effective dose of the antibody of claim 34, thereby treating said subject.
 40. A method of treating a subject suffering from, at risk for, or suspected of suffering from, a pathology ascribed to the presence of a sequence polymorphism in a subject, the method comprising: a) providing a subject suffering from, at risk for, or suspected of suffering from, a pathology associated with aberrant expression of a nucleic acid comprising a polymorphic sequence selected from the group consisting of SEQ ID NOS:1-651, or its complement; and b) administering to the subject an effective dose of an oligonucleotide comprising a polymorphic sequence selected from the group consisting of SEQ ID NOS:1-651, or by a polynucleotide comprising a nucleotide sequence that is complementary to any one of polymorphic sequences SEQ ID NOS:1-651, provided that said polymorphic sequence includes the nucleotide listed in Table 1, column 6 for said polymorphic sequence, thereby treating said subject.
 41. An oligonucleotide array, comprising one or more oligonucleotides hybridizing to a first polynucleotide at a polymorphic site encompassed therein, wherein the first polynucleotide is chosen from the group consisting of: a) a nucleotide sequence comprising one or more polymorphic sequences SEQ ID NOS:1-651; b) a nucleotide sequence that is a fragment of any of said nucleotide sequence, provided that the fragment includes a polymorphic site in said polymorphic sequence; c) a complementary nucleotide sequence comprising a sequence complementary to one or more polymorphic sequences SEQ ID NOS:1-651; and d) a nucleotide sequence that is a fragment of said complementary sequence, provided that the fragment includes a polymorphic site in said polymorphic sequence.
 42. The array of claim 41, wherein said array comprises 10 oligonucleotides.
 43. The array of claim 41, wherein said array comprises at least 100 oligonucleotides.
 44. The array of claim 41, wherein said array comprises at least 1000 oligonucleotides. 